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Bloodstream infections (BSI) constitute a common, serious, and potentially preventable cause 
of morbidity and mortality in children. Good knowledge of epidemiology, aetiology and the 
occurrence of antimicrobial resistance is essential for early effective empiric antibiotic 
therapy. Also, to identify areas for improved antimicrobial therapy and possible preventive 
measurements for BSI in different risk groups. 
The general aims of this thesis were to describe the aetiology, risk factors, and occurrence of 
bacteria resistant to antimicrobial therapy in children aged 0–17 years, with BSI under 20 
years.  
In papers I, II and IV, we found a crude BSI incidence rate of 25.5/100,000 children, aged 0-
17 years, over the study period, with differences between different ages and risk groups. 
From 15/100,000 in children, aged 3–17 years to 180/100,000 live births at neonatal wards 
(children 0–2 months), but 40/100,000 for 0–2 month-old children warded outside neonatal 
wards. Over the study period different strategies to prevent BSI attributed to a decreased risk 
for BSI. Introduction of vaccine against Streptococcus pneumoniae declined the incidence of 
BSI with 30% in children aged between 3 months and 2 years. Implementation of a a risk-
based intrapartal antibiotic prophylax program against early onset Streptococcus agalactiae 
BSI had most impact to reduce the incidende in new-borns. BSI in children without 
underlying co-morbidities has become rare and are caused by a limited numer of pathogens. 
In children with cancer, underlying co-morbidities and neonates warded at the neonatal wards 
the aetioloogy is much more diversed. S. aureus was the most prevalent pathogen. 
In paper III, we studied the antibiotic prescription, and concluded a changing pattern in the 
prescription of antimicrobial therapy, with a proportional decrease in the treatment of 
community-acquired infections and an increase in prophylactic therapy to specific risk groups 
of patients. 
In paper V, we found acquired antimicrobial resistance (AMR) in 9.2% of all invasive 
isolates. The trend for AMR increase for both Gram-positives and Gram-negative bacteria. 
The proportion of Enterobacterales producing extended-spectrum beta-lactamases (ESBL) 
increased from 1.6% to 14.1%. A high proportion (64.7%) of ESBL-producing strains was 
multidrug-resistant. During the last period, 6% of S. aureus were MRSA (methicillin-resistant 
Staphylococcus aureus). The oncology patient group had the highest proportion of ESBL-
producing Enterobacterales. A history of travel in the past six months to a non-Nordic 
country by the child or a household member was identified as a risk factor. 
In conclusion, the thesis adds knowledge about the aetiology and epidemiology of BSI in 
children from a Swedish perspective. The findings are highly important for designing empiric 
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 INTRODUCTION  
Childhood mortality has decreased globally during the past decades. Financial and political 
efforts to increase access to child-care services, an increase in maternal education, 
implementations of vaccines, HIV/AIDS, malaria, and tuberculosis programs are some 
crucial factors contributing to decreased mortality. Still, in total, 6.2 million children under 15 
years of age died in 2018, a child died every fifth second. More than half of those deaths were 
preventable, and infectious diseases caused approximately 60% of these deaths. (1-4) Among 
infectious disease, sepsis is a significant contributor to global morbidity and mortality in 
children. (5) In addition to mortality, infection contributes substantially to both paediatric 
emergency departments visits and hospital admissions, (6) 
 
Epidemiological studies of severe paediatric sepsis indicate that bacteraemia contributes 
substantially to severe sepsis and high mortality rates in children. (7-9) Bloodstream 
infections are, therefore, a significant and potentially preventable cause of death. 
Most of the global child mortality occur in low-income countries; although, even in high-
income countries, infectious diseases make a significant contribution to deaths in children. In 
the U.K., infection-associated deaths constitute 20% of all childhood death. (10) Early 
recognition, supportive therapy, and adequate antimicrobial therapy are cornerstones for a 
successful outcome. (11) Normal physiological, hemodynamic, and immunologic response 
and aetiology differ between adults and children. Therefore, it is not feasible to adapt adult 
data on the paediatric population. (12-16) Effective empirical antimicrobial therapy depends 
on good knowledge of the aetiology and local resistance pattern in bloodstream infections. 
(17, 18) Antimicrobial resistance is increasing globally and threatening paediatric health. 
National population-based data on the epidemiology of bloodstream infection are sparse and 




















2.1 SERIOUS INFECTIONS IN CHILDREN 
Epidemiological studies of the paediatric infectious diseases reveal an enormous burden of 
disease. Every single child will, at some point during childhood, get infected. A new-born is, 
in some respects, immunological naive, with a need for further maturation of the 
immunological system for acquiring effective resistance and resilience against 
microbiological agents. Contact with the environment is essential for the development of an 
effective immune system, and at the same time, it is potentially life-threatening. Bacterial 
colonisation early in life is universal for all children but comes with a risk for infections. 
There are several well-known risk factors for susceptibility to infections, but the question is 
why some infants only get colonised by bacteria. At the same time, some develop a severe 
infection and need hospitalisation and antimicrobial and supportive therapy to avoid a dismal 
outcome. Most infections are of viral origin, self-limiting and do not require antimicrobial 
therapy. 
Serious infections are defined as illnesses with a fever, that could cause disability or death if 
diagnosis and treatment are delayed. The conditions usually considered as serious infections 
are sepsis, bacteraemia, pneumonia, pyelonephritis, osteomyelitis, septic arthritis, meningitis, 
severe bacterial infections like mastoiditis, acute sinusitis, encephalitis, and also viral 
bronchiolitis and some viral infection, like, e.g. enterovirus, early in life. The overall risk for 
a serious infection in the child population varies, with studies showing less than 1% risk in a 
primary care setting, (19-21) but 10–15% risk during visits to the emergency department will 
suffer for a serious bacterial infections requiring antimicrobial and supportive therapy. (19, 
21, 22) In a European prospective multicentre study evaluating the role of severe paediatric 
infectious diseases in paediatric hospitals, children with suspected sepsis or a severe focal 
infection were included. Sepsis was found in 43.2% of all cases and had a worse outcome 
compared to severe focal infection. Both severity and mortality were higher in children 
with an identified causative pathogen than those with no causative pathogen. The mortality 
was 1–3% in previously healthy children and 7–10% in chronically ill children. (23) The 
mortality rate also differs amongst countries. Based on register data, children in the U.K. 
had a risk ratio of 1.84 to die of infectious diseases compared to Sweden. The mortality 
rates due to infections were 63.9/100,000 children under five years of age, and 10.5/100,000 
children between 5 and 15 years of age in the U.K., compared to 34.6/100,000 children under 
five years, and 7.85/100,000 children between 5 and 15 years of age in Sweden. (24, 25) 
Several factors probably explain these differences, but dissimilarities in the distributions of 
pathogens, e.g. N meningitidis, is one important factor. The distribution of some highly 
virulent bacteria differs amongst different areas and countries and affects disease severity and 
mortality rates. 
Data from Sweden Statistics on registered diagnosis for infectious diseases among hospital-
admitted children show the incidence of serious infections in Sweden (Figure 1a and 1 b). 
Pneumonia and urinary tract infection are the most prevalent infections, with 191 hospital 
admissions per 100,000 inhabitants for pneumonia, 159 per 100,000 for urinary tract 
infection, and 27/100,000 for sepsis in children aged 0–4 years as in 2018. (26) It is important 
 
 9 
to identify the child at risk of developing a life-threatening infection among other children 
who present with a benign, usually viral, infection with near to zero mortality. 
 
 
Figure 1a Discharge diagnoses in children 0-4 years of age admitted to hospital. 
 
 








































Serious infections in children 0-4 years of age




































































































































Serious infections in children 5-18 years of age
















2.2.1 Current and past definitions of sepsis 
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to 
infection, according to the 3rd International Consensus Definition for sepsis and septic 
shock. (27) Earlier definitions established at the first sepsis conference in 1991, and 
updated in 2001, focused on the host’s response to infection [systemic inflammatory 
response syndrome (SIRS)]. In 2005 a paediatric, age-specific definition was established at 
the International Paediatric Sepsis Consensus Conference. (28) The SIRS criteria did not 
necessarily indicate a dysregulated or life-threatening response. Furthermore, SIRS is 
present in many hospitalised patients, including those who never develop infection and 
never incur adverse outcome. The SIRS-based definition lacked specificity to identify 
children with a higher risk for mortality and yet missed 10% of children warded at intensive 
care unit (ICU) with infection and organ dysfunction. (29) Still, a definition is important for 
early identification, to promote adequate initial management and therapy, and to facilitate 
diagnostic registration for later evaluations. The current 3rd definition was established in 
2016 in response to the awareness that the previous definition of sepsis performed poorly, 
both in identifying early infections and in selecting patients in need for early, aggressive 
intervention and therapy in both adults and children. 
 
The sepsis-3 task force working with the new sepsis definition recognised that sepsis is a 
syndrome with no validated criterion standard diagnostic test. The task force evaluated the 
clinical criteria that best predicted in-hospital mortality, ICU mortality, and/or ICU 
admission > three days. The task force compared three different scoring systems: The 
sequential organ failure assessment (SOFA) score (initially the sepsis-related organ failure 
assessment), the Logistic Organ Dysfunction System (LODS), and SIRS. The SOFA-score 
and the LODS system were superior to SIRS in predicting mortality in ICU but similar to 
SIRS for patients outside the ICU with suspected infections. The sepsis-3 task force 
regarded SOFA as more well-known and more straightforward than the LODS system and 
therefore recommended the use of SOFA score.  
 
The SOFA score is a mortality prediction score based on the degree of dysfunction in six 
organ systems; the fraction of inspired O2 (FiO2), platelets counts, Glasgow Coma Scale, 
bilirubin, mean arterial pressure and creatinine, and is intended for patients admitted to 
ICU. A SOFA score of 2 or greater identifies a 3 to 11-fold increase of dying compared to 
SOFA score less than 2. (27, 30) However, there is, at present, no consensus on how to 
define organ dysfunction in children and thus the sepsis 3-task force excluded children in 
their analysis. There are several scoring systems for organ dysfunction in children, albeit all 
slightly different than SOFA. Validation of age-adjusted SOFA, the p-SOFA score has 
demonstrated excellent discrimination for in-hospital PICU mortality due to sepsis. (29, 31) 
P-SOFA is, therefore, a feasible scoring system to identify patients with a high probability 
to die in the PICU. However, p-SOFA (or SOFA) is not developed to help identify patients 
at risk for sepsis in the emergency department. In adults, quick-SOFA(q-SOFA), with an 
evaluation of the presence of altered mental status, systolic blood pressure below 100 
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mmHg and respiratory rate of 22/minute are used as criteria for early identification of 
patients with suspected sepsis to prompt clinicians to further investigate for organ 
dysfunction. Low blood pressure develops late in paediatric sepsis, and tachypnoea occurs 
early among febrile children with infections with near-zero mortality, as in bronchiolitis. Q-
SOFA has performed moderately in paediatric patients, with the area under the curve 
(AUROC) of <0.7, thereby interpreted as sub-optimal performance (29, 32). Evaluation of 
the paediatric early warning score systems (PEWS) revealed both higher sensitivity and 
specificity compare has qSOFA and with an AUROC of >0.8 implying good performance 
to identify children with sepsis (32, 33) 
To summarise, the definition of sepsis in adults is also adapted for children, but the 
paediatric criteria are undefined, and the optimal screening tool required for rapid 
recognition is still unclear. In the “Surviving sepsis” international guidelines, the authors 
recommended the implementation of a screening system for timely recognition of sepsis for 
the management of septic shock and sepsis-associated organ dysfunction in children. (11) A 
uniform paediatric sepsis definition is challenging. Pathophysiology, clinical presentation, 
and therapeutic approaches are under the influence of the maturation process and highly 
affected by age. It is important to be aware of the key differences in aetiology, presentation 
and resuscitation in children compare to adults. (12)  
 
 
2.2.2 Epidemiology of sepsis 
The risk for paediatric sepsis is not easy to establish. In a meta-analysis, based on paediatric 
population-based observational studies, the aggregated estimated incidence of sepsis was 48 
(95% CI 27–86) cases per 100,000 person-years for sepsis, 22 (95% CI 14–33) cases per 
100,000 person-years for severe sepsis, and 2202 (95% CI, 1099–4360) cases per 100,000 
live births for neonatal sepsis. The crude mortality rate was 9–20% and varied from 1–5% 
for sepsis, 9–20% for severe sepsis to 11–19% for neonatal sepsis. (5) The burden of severe 
sepsis in children admitted to paediatric intensive care units (PICU) was evaluated in a 
global point prevalence survey conducted on five days throughout 2013–2014 in 26 
countries (the SPROUT study). The prevalence of children with severe sepsis was 8.2% 
(95% CI, 7.6–8.9%), and the mortality was 25%. In 40% of the sepsis cases, the primary 
site of infection was the respiratory tract, and 26% of patients had a positive blood culture. 
(7) Similar prevalence rates are observed in other studies, but also are both lower and 
higher rates of children with sepsis. 
 
The prevalence rates differ significantly depending on what inclusion criteria are adopted; 
inclusion of patients with a combination of infection and organ dysfunction, or inclusion 
based on diagnostic codes for severe sepsis and septic shock. A tenfold difference in the 
prevalence rates and mortality can be attributed to the criteria used. Among hospitalised 
children in the U.S. the prevalence was 3.1%–7.0% when using combination code compare 
to 0.45%–0.84% using the severe sepsis ICD-9-CM codes. (8, 34, 35) Similar differences 
are reported for the mortality rates. The 28 days mortality for combination code patients 
were 4.4%–8.2% and 15.4–21.2% in children with codes for severe sepsis. (6,30) 
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In Sweden, the annual incidence rate for severe sepsis was reported to be 687/100,000 
adults with in-hospital mortality of 19.8%, (36) giving an estimation of 40,000 cases per 
year and 6000 deaths. The incidence of paediatric sepsis in Sweden is not known. 
According to diagnose codes for children 0–4 years of age discharged from hospitals, the 
incidence for sepsis was 118/100,000 children in 2018. (26) 
 
2.2.3 Increasing incidence and decreasing mortality  
Retrospective register studies based on children warded at hospitals with diagnosing codes 
according to the International Classification of Diseases (ICD) codes for severe sepsis or 
septic shock 995.95 or 785.52 respectively, reveal increasing incidences of sepsis. In the US, 
the estimated incidences increased from 0.56/1,000 children in 1995 to 0.89/1,000 children in 
2005 (35), and from 0.93/1,000 children in 2006, to 1.59/1,000 children in 2012. (37) A 
prospective study from Australia and New Zealand reported an average yearly increase of 
0.08–0.09 cases per 100,000 children in paediatric sepsis at ICUs between 2002–2013. (38) 
Also, the prevalence of children hospitalised for sepsis increased in the U.S. In studies 
including patients with infection, in combination with a diagnose code for organ dysfunction, 
an increase from 3.7% to 4.4% and from 0.4% to 0.7% for the patient diagnosed ICD-9-CM 
codes for severe sepsis codes respectively (34) At the same time, sepsis mortality rates 
declined between 2004 and 2012 in all categories. (9, 34)  
 
Table 1 Summary of studies on paediatric sepsis 
Author Study 
year 
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Bloodstream infections (BSIs) are identified as one of the most severe causes of sepsis. 
Following a similar trend, the decline in mortality from BSI in children correlates with the 
decline in mortality from high virulent pathogens, concomitant with increase in pathogens 







2.3 BLOODSTREAM INFECTIONS  
2.3.1 Definition of bloodstream infections 
Bloodstream infection (BSI) and septicaemia are sometimes interchangeably used. 
Septicaemia is like a BSI, bacteria in blood in combination with signs of an infection, but 
usually refers to severe symptom fulfilling diagnostic criteria for severe sepsis. BSI is an 
infection with a high potential for developing into sepsis, severe sepsis, and septic shock. BSI 
is identified as isolation of viable bacteria or a fungal pathogen in a blood culture bottle, 
bacteraemia (or fungaemia) in combination with clinical signs of infection. Bacteraemia 
could occur, either as a result of spread from an initial focal infection reflecting a 
deterioration of the disease, or during daily activities like toothbrushing, or when a natural 
physical barrier, such as skin, is compromised. In the case of toothbrushing, bacteraemia is 
usually transient and a clinically benign condition where the host immune system eliminates 
the bacteria from the blood. In the circumstances with impaired host immunity, the presence 
of foreign material, or anatomical lesions could lead to bacteraemia, and the usually benign 
situation could result in clinical infection, a BSI, or focal infections, such as osteomyelitis, 
with a risk for substantial morbidity, sequelae and mortality, (Figure 2). 
 
Figure 2 Serious infection with the potential to develop to sepsis 
 
2.3.2 Detection of bacteria in the blood 
There are several laboratory methods to identify microorganisms. The different methods for 
detecting bacteria in blood are microbial cultures, detection of bacterial 16S rDNA, targeted 
PCR, detection of specific bacterial structures, and detection of antibody developed against a 
specific pathogen. Blood culture is the gold standard to detect bacteria in the blood. An 
isolated organism in the culture is considered a positive blood culture. However, a culture 
requires viable bacteria, and the method is surrounded by some problems, i.e. sampling 
volume, contamination, pre-analytic time, up to 48 hours turnover time before a result. In 
children, a small blood volume is considered to contribute a significant problem for the 
opportunity to catch a viable bacterium. The higher the blood volume cultured, the higher 
yield. Modelling data and clinical studies on adults with BSI reveal that the bacterial 
concentration ranges from 0.01–1 CFU/mL in 50% of BSI cases. The bacterial load is 
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positively correlated to the severity of the infection and could exceed 100 CFU/mL for severe 
clinical infections with a high bacterial load. The bacterial concentration is concluded to be 
comparable between children and adults. (42) The sensitivity for blood cultures has been 
estimated to be 95% when 3 CFU are sampled, which implies that a total volume of at least 
30 ml is required for detecting most BSI low-level bacteraemia (<10 CFU/mL) or very low-
level of bacteraemia <1 CFU/mL. (43) The majority of neonatal children (64%) and of 
children two months to 13 years of age (60%) has been found to have low-level bacteraemia 
with <10 CFU/mL and a substantial proportion of neonates and children >2 months had very 
low-level bacteraemia with <1 CFU/mL. (44) The sensitivity for paediatric blood cultures has 
been estimated to be 40% when collecting 2 ml blood and 75% when collecting 6 ml. (45) 
The current recommendation for the correct blood volume in paediatric blood cultures is 
based on the assumption that it is safe to collect 4.0–4.5% of the child’s total blood volume 
which is required to detect low concentrations of pathogens in the blood. The recommended 
volume varies between centres, approximately; 1–1.5 mL for children weighing less than 4 
kg, 3 ml for children 4–7.9 kg, 6 ml for children 8–11 kg, and 7 ml for >11 kg. (46)  
 
Table 2 Blood sampling for culture in children 





• 23% of children with BSI 
>2 months of age 




Low level • 64% of neonate 
• 60% of children  
30 ml are required to achieve a 





Severe infections 3 ml  
   
The blood volume in 
children 
 70–80 ml/kg 
Accepted as safe sampling blood volume  4–4.5% 
Recommended volume <4 kg; 1–1,5 mL    4–7.9 kg; 3 mL    8–11 kg; 6 mL    >11 kg; 7 mL 
 
Studies on the amount of blood that was actually retrieved in paediatric blood cultures found 
that 46% of the submitted blood culture bottles contained adequate blood volume and blood 
cultures with adequate blood volume were more likely than those with an inadequate blood 
volume to yield positive blood culture results. (47) 
In most studies regarding BSI, about 85% of all collected samples are negative and with 
varying degree of pathogens that could be considered as possible contamination of 
commensal skin microbiota. Low positive rates have raised the question of the utility to 
obtain a blood culture. For children admitted to hospital due to community-acquired 
pneumonia, the rate of a positive blood culture is under 5% on average, but significantly 
higher in children with complicated pneumoniae. In pneumonia, complicated with pleural 
effusion, lung abscess, necrosis and drainage, or coincidence of distal site of infection had up 
to 75% positive blood culture rates. (48, 49) Children with positive culture had a longer 
duration of fever before admission and significantly higher CRP levels than blood culture-
negative children. There was no difference between the bacteriaemic and nonbacteremic 
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groups for WBC counts or for the other more common (severe) infections. In children 
admitted to hospital with suspicion for pyelonephritis/UTI blood culture is also a part of the 
diagnostic evaluation. For UTI, there is an inverse correlation between age and positive blood 
culture, elevated creatinine, and pathological ultrasonography are also reported as a risk 
factor for positive blood culture in children (50, 51).  
Given the problems for blood cultures with low sensitivity and up to 48 hours to present a 
preliminary result, there is a need for other diagnostic tools for BSI and sepsis. During the last 
two decades, molecular methods to detect bacterial DNA has been developed. Bacteria are a 
prokaryote organism and lack an enveloped nucleus. The protein-producing, ribosomes, in all 
prokaryote cells have different subunits. The smallest subunit, 16S, is found in all bacteria 
and a highly conserved part similar in all bacteria that could be detected by PCR, and another 
hypervariable, species-specific, region. With 16S rDNA sequencing, bacteria present in a 
sample can, in a culture sequencing manner, be identified to the species level. The 16SrDNA 
sequencing for normally sterile fluids like cerebrospinal fluid, synovial fluid and pleural 
effusions are already in clinical use. The use of 16S rDNA sequencing in blood has proven 
not to work so well due to low bacterial concentration, and no method has been established 
for clinical use even if some have shown promising results. (52) (53) 
 
2.3.3 Epidemiology of BSI  
In Table 3, available data on BSI are summarized. Since there are major differences in study 
populations and primary endpoints in these studies it is difficult to draw general conclusions. 
There are some similar observations reported such as an decrease in incidence over the past 
years (54-56) and an increase of children with underlying co-morbidity leading to a change in 
the spectrum of pathogens associated to BSI (38,39.56).  
  
Table 3 Summary of available studies on BSI in the paediatric population 
  Sepsis in 
PICU 
with BSI mortality 
Weiss, (7) The SPROUT-study 8.2% 26% (20–40%) 
Ruth, (9)  49,153 PICU admitted 7.7% 67% 14.4% 
Boeddha, (57)  the EUCLID study n=795 42% 6% 
Spaulding, (54)  BSI in 162 U.S paediatric hospital 0,3% 5% 
Ruiz-Ancona, (58)  Incidence of BSI in Spain  224/100,000  
Skogberg, (59)  Incidence of BSI in Finland <1 year                                                     514/100,000
33/100,000 
18%
0,6%  1–13 years 
Agyeman,(17) Incidence of BSI in 
Switzerland 
0–17 years of age 





Greenhow, (19, 55)  Incidence of BSI in U.S.  7–59 days of age. 0.57/1,000  
  3–to 36 months 21/100,000  
Laupland, (56) Inc. of BSI in Canada 0–17 years of age 53/100,000 5% 
Henderson, (60) Incidence of BSI in the 
U. K 
1–11 month of age 






It is also evident that the epidemiology is distinctly age-related. The prevalence for infants, 
<1 year of age, is considerably higher than for children over one year of age. The 
epidemiology is, besides from the occurrence of co-morbidities, distinctly age-related. The 




The aetiology of paediatric BSI has changed considerably during the last three decades. The 
introduction of vaccines against previously dominant pathogens has been effective. (61) 
Improvement in public health and access to healthcare facilities and antimicrobial therapy has 
reduced community-acquired infections. However, progress in the treatment of prematurely 
born children, oncology patients, cardiovascular patients, and other groups of children with 
severe co-morbidities has led to a patient category that requires more frequent, and longer 
hospital-stays, with a risk for health-care-associated infections. (62, 63) 
The classical, highly virulent paediatric pathogens that cause community-acquired infections 
in otherwise healthy children is declining, and paediatric BSIs are partly replaced by other 
bacteria in more vulnerable patients, and more often cause hospital-acquired infections. 
The most frequently isolated pathogens in paediatric BSI are Staphylococcus aureus, 
Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus spp, Streptococcus 
agalactiae, coagulase-negatives staphylococci (CoNS), Escherichia coli, Klebsiella 
pneumoniae, Salmonella spp. and, Pseudomonas aeruginosa (19, 39-41, 64-68). The 
aetiology is related to age, patients’ characteristics, and specific hospital settings. (19, 40, 41, 
67, 69) 
2.3.4.1 Staphylococcus aureus 
Staphylococcus aureus is one of the most frequently isolated pathogens in paediatric BSI 
after implementation of HiB-vaccines and PCV vaccines. S. aureus is a skin coloniser also 
found in anterior nares. A wounded skin or a depleted mucosal barrier causes the bacteria to 
leave its equilibrium state of a commensal and become infective. S. aureus infections vary 
from mild skin infections to severe life-threatening infections with complications of 
bacteraemia, such as endocarditis. Neutrophils play an essential role in the human defence 
against S. aureus, and premature infants with immature neutrophil or other patients with 
impaired neutrophil function are at greater risk for infections. (15) S. aureus also have the 
capacity to produce several toxins involved in more severe conditions. (70, 71)  
• PVL: Necrotising pneumonia with Panton-Valentine Leucocidin (PVL) toxin-
producing S. aureus.  
• Exfoliation of skin: Staphylococcal scalded skin syndrome (SSSS) mediated by 
exfoliating toxins A and B, that cleave desmosome junction in the epidermis, causing 
painful blisters and exfoliation of the skin. 
• TSS-1: Toxic shock syndrome with a rapid onset of massive production and release of 
cytokines. The S.aureus toxin TSS-1 acts as a superantigen and activates a large 
proportion of T-cells that release a cascade of pro-inflammatory cytokines. 
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Healthcare-associated S. aureus BSI (SAB) is commonly related to indwelling catheters. 
Complications occur in 30% of cases, including thrombosis, endocarditis, and recurrence of 
infections. The risk for a complication is related to the time of bacteraemia. (72) The 
possibility of saving a central line of patients in SAB, but without signs of complication, has 
been discussed. Salvaging of the central line is feasible in the majority of children, and 
attempts to clear the bacteraemia can be considered for 48 (73) to 72 hours without increased 
risk for complication. (74)  
 
2.3.4.2 Streptococcus pneumoniae 
Streptococcus pneumoniae (pneumococcus) is a pathogen that colonises the mucus 
membrane in the nasopharyngeal tract in children and their close contacts. A viral upper 
respiratory tract infection often precedes an invasive pneumococcal infection with 
pneumonia, bacteraemia, sinusitis, other ear-nose-throat infections, and meningitis. The 
species has over 90 different serotypes with different pathogenic capacities and geographical 
distribution. (70, 71) Efforts to include serotypes found in invasive infections for preparing 
vaccines have been successful. Pneumococcal conjugate vaccine (PCV) targeting the most 
prevalent serotypes has decreased the incidence of invasive pneumococcal diseases 
significantly. However, Streptococcus pneumoniae has a substantial aetiology in paediatric 
sepsis. (75) 
2.3.4.3 Streptococcus pyogenes 
Streptococcus pyogenes are usually called Group A Streptococcus (GAS) following the 
Lancefield classification of beta haemolysing streptococci. The bacteria are transmitted 
through droplets from one person to another and cause pharyngotonsillitis, mild skin 
infections to more severe local infections, and life-threatening invasive infections. GAS can 
produce toxins and cause scarlatina and life-threatening streptococcal toxic shock syndrome. 
After an acute GAS infection, immune-complex reaction following a risk of developing 
glomerulonephritis and rheumatic fever, which is rare. (70, 71) 
2.3.4.4 Streptococcus agalactiae  
Streptococcus agalactiae is often classified as beta-haemolytic Group B streptococcus 
(GBS). It is a part of the commensal intestinal microbiome in 30% individuals and contracts 
the vaginal flora in those who are colonised. Vaginal GBS colonisation confers a risk of 1.1% 
for early-onset (EOS) GBS infections after vaginal delivery. (76) Colonisation is also 
associated with preterm birth, especially when there is evidence of maternal ascending 
infection (bacteriuria). (77) GBS is the most common neonatal infection, with a case fatality 
rate of 9.6%. (78) Late-Onset GBS infection is associated with maternal colonisation but is 
also evident in cases without colonisation, indicating that horizontal acquisition from non-
maternal caregivers may also be a part of pathogenesis. GBS can be isolated from 25% of 
milk samples of colonised, breastfeeding mothers, though milk also contains protective 
antibodies (unspecific secretory-IgA), and protective human oligosaccharides against 
invasive GBS infection. (79, 80) There is no recommendation of withholding breastfeeding in 




2.3.4.5 Enterococcus species 
Enterococcus faecalis and Enterococcus faecium are a part of the intestinal microbiome and 
are much less virulent than S. aureus, S. pneumoniae, GAS and GBS. They appear as 
opportunistic infections, and appear in polymicrobial cultures, where the significance of their 
presence could be challenging. Children with comorbidities and extended hospitalisation with 
indwelling medical devices are at a higher risk for infection. Prolonged bacteraemia could 
cause endocarditis. Urinary tract infection occurs in children with underlying urinary 
abnormalities or urine catheters, and a normal urinary tract. (71)  
2.3.4.6 Coagulase-negative staphylococci 
Coagulase-negative staphylococci (CoNS) is a group of over 40 bacteria, the most 
noteworthy are Staphylococcus epidermidis, S. saprophyticus, S. haemolyticus, and S. 
lugdunensis. Staphylococcus epidermidis is the most common species and is a part of normal 
skin commensal flora. It produces a biofilm on foreign material, and like S. aureus, the host 
defence depends on neutrophilic phagocytosis (bacterial killing). Infections in children with 
indwelling catheters, particularly in premature neonates and children with neutropenia, puts 
them at risk for CoNS infections. CoNS contribute to 50% of neonatal BSI. In otherwise 
healthy children, isolated CoNS are usually considered contaminants. (71) 
2.3.4.7 Enterobacterales 
Escherichia coli, Klebsiella spp., Salmonella spp., Enterobacter spp., Serratia, Proteus spp., 
Citrobacter spp., Shigella spp., Hafnia and Morganella are all members of the family of 
Enterobacterales colonising the intestinal tract. Members of this family vary from highly 
virulent pathogens to low virulent commensals that can still be considered significant in 
patients with underlying co-morbidities contracting infections during hospital care. 
E. coli is the most commonly isolated species of the Enterobacterales and compromise >90 
of all urinary tract infections. E. coli has become the most common pathogen among neonates 
and the second most common in children after the neonatal period in the U.S (54)  
2.3.4.8 Haemophilus Influenzae 
Haemophilus influenzae is a gram-negative bacterium that is either capsulated, with the outer 
lipopolysaccharide layer of the cell wall surrounded by a polysaccharides capsule, or non-
capsulated. As for other capsulated bacteria, differences of the polysaccharides composition 
constitute a base for its identification together with its ability to escape or activate the host 
immune defence. Encapsulated H. influenzae isolates are classified into six serotypes, a, b, c, 
d, e, and f. Non-encapsulated H. influenzae colonises the nasopharyngeal mucus membrane in 
up to 80% of the population, and the capsulated form colonized 5–10% of the population 
before the HiB vaccine era. Type B was the most common and highly virulent serotype. 
Similar to the infection from other encapsulated bacteria, children aged between 6 months 
and 2 years, without protective maternal antibodies and with a lower ability for opsonisation 
and phagocytosis, are the largest risk groups for invasive infection. Individuals with asplenia, 
sickle cell anaemia, complement deficiency, and immunodeficiency are other risk groups for 
invasive infections. (68(82, 83)) Invasive infections could occur in individuals with risk or in 
children with a preceding viral upper respiratory tract infection. HiB infection with 
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meningitis, bacteraemia, epiglottitis, cellulitis, pneumonia, and osteoarthritis contributed to 
considerable morbidity and mortality before the introduction of the Hib vaccine. 
The highly effective and safe protein-polysaccharide conjugate Hib vaccines have been used 
for 30 years and have almost eliminated Hib disease. Most Haemophilus infections are now 
due to the non-capsulated form, the non-typeable Haemophilus influenzae. (84) ) 
2.3.4.9 Neisseria meningitidis 
N. meningitidis colonises the nasopharyngeal mucus membrane in 20–25% of the adult 
population. Transmission occurs from an infected person to the person by close direct or 
indirect contact. Most contaminated individuals develop no or mild symptoms (sore throat 
and upper respiratory tract infection) in a few days, before developing protective antibodies 
and becoming asymptomatic carriers for some months. In up to 1–3 % of infected 
individuals, the bacterial acquisition leads to a more severe infection with septicaemia (25%), 
meningitis (15%), a combination of both symptoms (60%), or other focal infections like 
conjunctivitis. The lipopolysaccharide layer of the bacterial cell-wall has an endotoxin that 
causes immune activation.(71) However, it is also surrounded by a polysaccharides capsule 
that causes invasive infection. There are twelve encapsulated serotypes, 6 of which, A, B, C, 
W135, W and Y, cause the majority of invasive infections. The distribution of serotypes 
varies by geographical region . Serogroup A dominates the African meningitis belt, whereas 
serogroup B and C dominate Europe.  
For an unknown reason, N. meningitidis is rare in Sweden but still life-threatening for those 
contracted with invasive infection. The crude incidence for invasive N. Neisseria infection is 
0.6/100,000 individuals, which correspond to approximately 50–60 cases per year in Sweden, 
of whom 16% are 15–19 years old, and 11% are 0–4 years old. (85) Serogroup MenW is the 
most frequent isolated serotype.(86) Worldwide, serogroups MenB and MenC dominate. 
High endemic areas with >10 cases/100,000 individuals and epidemics with 1000/100,000 
individuals occur. In countries with higher endemic rates, the mortality is reported to be 
10%(87). Our low incidence of invasive N. meningitides implies our crude mortality rates of 
BSI 
 
2.3.5 Age-dependent incidence 
The overall incidence for BSI is approximately 140–160/100,000 individuals, based on 
relatively limited number of population-based studies, mostly in high-income countries and 
sometimes without calculating age-adjusted differences in incidence rates. (88) Studies in 
low-income countries reveal a far higher risk for BSI in children, with 8–38% with BSI of all 
hospital admission, but figures for incidence are not easily accessible. (84) For children in 
comparable settings the incidence is reported as follow: 3–4/1,000 live births, 0–28 days of 
age in Sweden (89), 2.3/1,000 for late-onset sepsis (LOS) in Italy (90), and 1.42/1,000 in 
France (91) The Swiss Paediatric Sepsis Study reports 1.43/1,000, 0–28 days of age, but only 
0.28/1,000 for community-acquired LOS (92). The author concluded major differences in 
epidemiology, host characteristics, and patient-centred outcomes between EOS, hospital-
acquired LOS, and community-acquired LOS. After the neonatal period, the incidence 




2.3.6 Community-acquired, Hospital-acquired or Healthcare-associated 
infections BSI in children 
Infections identified from samples taken more than 48 hours after hospitalization, has since 
the early 70s, been categorized as hospital-acquired or nosocomial infections (HAI), and 
infections identified in samples within 48 hours after admissions as community-acquired 
infections (CAI). The definitions were implemented for surveillance of nosocomial infection. 
(93) The rationale for the distinction was evidence of a different aetiology between the two 
categories, with implication on empirical antimicrobial therapy, and an aim to find measures 
to prevent nosocomial infection, increase the quality of hospital care and improve treatment 
outcome (94, 95). CAIs were predominantly due to organism with virulent pathogens capable 
of infecting otherwise healthy persons. HAI was associated with exposure to invasive devices 
and procedures with staphylococcus and gram negatives as the dominant flora, table 4. (95) 
 
Table 4 Distribution of pathogens in hospital acquired infection. Garner et al. The Journal of pediatric 1972 
 
Children at higher risk for HAI include those with invasive devices and underlying co-
morbidities requiring hospital care, those with a breached host defence, or those who are 
immunocompromised. These groups of patients have increased over time, and the health care 
organisation has developed, resulting in lengthy hospital stays and increased outpatient and 
home treatment of complex conditions involving invasive devices. This change has resulted 
in typical HAI infections presenting as a CAI, and the CAI/HAI dichotomy does not reflect 
the most plausible aetiology in BSI. (96) Health care-associated infections (HCA or HCAI) 
have, therefore, been introduced. HCAI are infections that occur because of health care. Still, 
there is inconsistent use of these criteria, and there is a lack of evidence to distinguish 




2.4 ANTIMICROBIAL RESISTANCE 
2.4.1 Definitions 
Antimicrobials are a group of drugs that antagonise the growth of living microorganism, 
including bacteria (antibiotics), viruses (antivirals), fungi (antifungals) and parasites 
(antiparasitals). Antimicrobial resistance (AMR) is the ability of a microorganism to resist the 
action of an antimicrobial agent. The microorganism tries to adapt to its environment to 
survive. In the case of bacteria, antibiotic resistance (ABR) is the ability of bacteria to resist 
the action of an antibiotic. There are several classes of antibiotics that act on different targets 
and are designed for certain bacteria. Some bacteria are intrinsically resistant to certain 
antibiotics. The global threat of AMR is when susceptible bacteria acquire resistance through 
genetic changes because of their adaption under the antibiotic stress. Heavy use of antibiotics 
acts as a driver for the development of acquired antimicrobial resistance. Once the 
microorganism becomes resistant, it can spread between humans, animals, and the 
environment. If a bacterium is resistant to three or more classes of antibiotics, it is called 
multidrug-resistant (MDR). ABR occurred soon after antibiotics were discovered. An 
overview of antibiotics and the following resistance is shown in Figure 3. 
Figure 3 A summarised overview of the introduction of antibiotics and subsequent resistance 
 
2.4.2 The burden of antimicrobial resistance 
AMR challenges effective therapy against infections, and reports reveal an enormous global 
burden. National reports from five out of six WHO regions report E.coli and Klebsiella 
pneumoniae are 50% resistant against third-generation cephalosporins, fluoroquinolones, 
whereas S. aureus is resistant against methicillin. (97) Globally, 700,000 people are estimated 
to die because of antimicrobial-resistant infections every year, with 50,000 deaths occurring 
in Europe and the U.S. (98) The estimation of the global burden of AMR is, in general, based 
on studies involving low sample size, and patients with severe infections, (97). The estimated 
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burden of AMR is partly extrapolated from European data. Such extrapolation may lead to 
uncertain results, emphasising the need for more comprehensive antimicrobial surveillance 
data at a local level for both community-acquired infections and healthcare-associated 
infections. (99, 100) To tackle the threat of AMR and the need for surveillance data, the 
WHO launched a global antimicrobial resistance surveillance system (GLASS), providing a 
platform for collection, analysis, and sharing of standardised AMR data. (101) The European 
data on AMR is retrieved from hospitals across Europe. These are mostly tertiary hospitals, 
and the data regarding invasive infections diagnosed in the hospital are reported to the 
European Antimicrobial Resistance Surveillance Network (EARS-net). The European Centre 
for Disease Prevention and Control (ECDC) publishes this data. The ECDC estimated that 
670,000 infections occur in the EU/EEA due to bacterial resistance to antibiotics, and 
approximately 33,000 people die annually, as a direct consequence of AMR infections. Many 
of these infections (63%) were considered hospital-acquired infections (HAIs). AMR 
infections have increased in all countries reporting to EARS-Net. (102) From a European 
point prevalence survey in 2016–2017, 8.9 million HAIs in hospitals and long-term facilities 
were identified. A microorganism was isolated in 53% of hospital-admitted patient, one-third 
of the bacteria associated with HAI were resistant to antibiotics, and more than half of the 
HAIs were considered preventable. (103) 
2.4.3 Development of resistance 
The emergence of AMR is, as mentioned, a natural evolutionary response to antimicrobial 
exposure. Antibiotic overuse and inappropriate antibiotic use are the main reasons for the 
increase in AMR. Studies over the antibiotic use in several European countries report that up 
to 50% of the prescribed antibiotics could be considered unnecessary or inappropriate(104-
107). 
In countries with high AMR occurrence, there is also a high antibiotic consumption. In the 
WHO report on surveillance of antibiotic consumption 2016–2018, the total antibiotics 
consumption in humans ranged from 4.4 to 64.4 Daily Delivered Doses (DDD)/1000 
inhabitants. Third-generation cephalosporins, quinolones and carbapenems, categorised as 
“Watch antibiotic” due to their high potential for AMR development, accounted from less 
than 20% to over 50% of antibiotics consumed. (108). In Europe, the average total 
consumption of antimicrobials in 2018 was 20.1 DDD/1000 inhabitants with a country range 
of 9.7–34.0 DDD. (109) The total consumption in Sweden was 11.1 DDD/1000 inhabitants in 
2019 with a decreasing trend since 2011; a trend also evident in children. (110) The 
differences in antibiotic consumption between countries are substantial when it comes to 
consumption in the community. The consumption in hospital settings varies little. In 2018, 
the EU/EEA population-weighted, mean consumption of antibacterials for systemic use in the 
hospital sector was 1.8 DDD/1000 inhabitants per day, ranging from 0.8 in the Netherlands to 
2.5 in the U.K., and 1.65 in Sweden. (111) Paediatric antimicrobial use is declining in 
Sweden (110). Antimicrobial consumption globally remained relatively constant in high 
middle-income countries between 2011 and 2015. (112) Still, the prevalence of AMR 
increased. 
Antimicrobial usage in animals is a key contributor to total antimicrobial consumption. 
Sweden prohibited the administration of growth-promoting antibiotics to healthy animals in 
1986. The sales of antibiotics for administration to animals in Sweden were 9.5 tonnes, or 12 
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mg/kg animal in 2019 (compare to 61 tonnes or 90 mg/kg in humans). (110) The median sale 
in European countries was 61.9 mg/kg, range 3.1–423 mg/kg. The countries with the highest 
sales for animal use also had the highest occurrence of AMR. (113) Statistical modelling 
estimated a global average of 365 mg/kg antibiotics used in 2010, with a projected 67% rise 
until 2030. (114) A study comparing data of veterinary antimicrobial use with national 
reports of AMR prevalence found a strong positive correlation between AMR and antibiotic 
use in animals, also suggesting that antimicrobial use in animals is capable of explaining 
variations amongst AMR status between nations (115). The causality has been debated but 
has also been supported (116-118) and considered to be established. (119) 
 
2.4.4 Interactions between antimicrobials and antibiotic 
Antimicrobial agents, antibiotics, all have a mutual aim to kill bacteria. The killing is 
achieved through a variety of mechanisms of action, target sites, chemical structures, and 
bacteriostatic (inhibiting) or bactericidal (killing) effects. Bacteriostatic antibiotics need a 
functional immune system to achieve sufficient efficacy or a complementary antibiotic. There 
are five main target sites for antimicrobial action; (120) 
•  Cell wall synthesis  
• Protein synthesis  
• Nuclein acid synthesis 
o DNA or RNA 
• Metabolic pathways 
• Cell/plasma membrane 
function 
Bacteria are prokaryotic 
organisms. In contrast to 
the eukaryotic organism, 
prokaryotes do not have a 
cell nucleus. Bacterial 
DNA is formed in a single 
circular chromosome, and additional DNA is carried in plasmids. The plasma membrane is 
covered by a protective cell wall. The primary and unique component of the bacterial cell 
wall is peptidoglycan. In gram-positive bacteria, the peptidoglycan forms a thick layer 
surrounding an inner plasma membrane. In gram-negative bacteria, the peptidoglycan layer is 
thin and overlaid by lipopolysaccharide and lipoprotein layer. The thick hydrophilic cell wall 
in gram-positive bacteria retains the violet colour while gram-negative bacteria lose the violet 
colour and appear pink under a microscope, following gram staining. External to the cell 
wall, some bacteria have a protective polysaccharide capsule. The pathogens Streptococcus 
pneumoniae, Haemophilus influenzae type B, Neisseria meningitidis are examples of bacteria 
with a capsule that protects against phagocytosis by host cells. Those layers are important for 
the characteristics of the bacteria. The cell walls and their reproductive process are also the 
targets for antimicrobial agents. (120) 
 
 
Figure 4 Target sites for antimicrobial actions 
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2.4.4.1 Inhibitors of cell wall synthesis 
Synthesis of the bacterial cell wall includes several steps, including the production of cell 
wall subunits, transport through the plasma membrane and insertions into the wall. The 
different stages of synthesis are potential targets for antimicrobial actions. Inhibitors of cell 
wall synthesis are active against bacteria that are in their growth phase. The most important 







➢ Bind to Penicillin Binding 
Proteins (PBPs) in the cell 
wall 
➢ Gram-negatives; β-lactams 
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2.4.4.2 Protein synthesis inhibitors 
Several antimicrobials inhibit different steps in the synthesis of essential bacterial 
components, from chromosomal material to proteins. They are separated into two groups, 
those acting on the ribosomal subunit 30S, or 50S, of the bacterial ribosome complex. 
Aminoglycosides inhibit bacterial RNA in two ways, leading to their bactericidal effect. 
Other protein synthesis inhibitors have a bacteriostatic effect. 
 











Interferes with the 
formation of the initiation 





Binds to elongation factors  





2.4.4.3 Inhibitor of nucleic acid synthesis 
This mechanism of action includes inhibition of DNA replication or RNA polymerase 
activity. Fluoroquinolones interfere with DNA synthesis by blocking DNA gyrase (more 
effective against gram-negative bacteria) and/or topoisomerase IV (more effective against 
gram-positive bacteria). Rifampicin, another nucleic acid synthesis inhibitor, binds to RNA 
polymerase. In both cases, the cell dies, and the effect is bactericidal. 
  








2.4.4.4 Inhibition of bacterial metabolic pathways 
Both sulfonamides and trimethoprim inhibit precursors in nucleic acid production and have a 
bacteriostatic or bactericidal effect. Metronidazole is a prodrug that activates in anaerobic 
cells leading to reactive compounds that interact with nucleic acid and proteins and have a 
bactericidal effect. 
 
• Sulfonamides ➢ Blocks enzymatic activation required for the synthesis for 
purines and pyrimidines and thereby the synthesis of 
nucleic acid synthesis 
• Trimethoprim ➢ Same as sulfonamides but downstream synthesis pathways 
• Nitroimidazoles 
- metronidazole 
➢ interaction and breakdown with bacterial DNA 
 




➢ Depolarised and disrupting the cytoplasmatic membrane in 
gram-positive bacteria, with a bactericidal effect 
• Polymyxin 
- colistin 
➢ Disrupt the phospholipid structure in gram-negative cell 









2.4.5 Different mechanism of AMR 
In the context of AMR, bacteria have three fundamental ways to respond to antibiotics; they 
are either susceptible or naturally resistant, or they acquire resistance. Natural or intrinsic 
resistance restricts antimicrobial drug activity for all members of a specific species. Acquired 
resistance is the bacteria’s way to escape from the threat of antibiotics and survive. Bacteria 
develop resistance as an adaption to survive antibiotic pressure; favouring those with the 
ability to resist the antibiotics. Resistance arises from bacterial chromosomal mutations. 
These mutations result in the synthesis of altered proteins that increase the bacterial ability to 
resist antibiotic killing or inhibition. Bacteria can develop resistance in different ways. 
➢ Production of enzymes 
• β-lactamases, including ESBL, are enzymes that inactivate β-lactam antibiotics by 
hydrolysing their β-lactam ring, inhibiting their ability to bind to PBP in the cell wall.  
• Aminoglycoside modifying enzymes 
• Macrolide- and lincosamide inactivating enzymes 
• Chloramphenicol acetyltransferases 
• Quinolone inactivating enzymes 
 
➢ Alteration of outer-membrane permeability in gram-negative bacteria resulting in 
inhibited passage of antibiotic molecule into the cell. 
➢ Alteration of target sites 
• PBPs, mutations in the synthesis of PBP alter proteins and impair binding of β-
lactam antibiotic to PBP in the cell wall. 
• Methylation of ribosomal RNA confers resistance to macrolides and lincosamides 
• Mutations in the chromosomal genes for DNA gyrase confer resistance to 
fluoroquinolones 
 
➢ Efflux pumps, mediated by transmembrane protein channels that actively export 
antimicrobial agents out of the cell. This is the main mechanism for resisting 
tetracyclines, and also a mechanism for resisting macrolides and fluoroquinolones. 
 
➢ Alteration of metabolic pathways, caused by mutations in the antimicrobial chromosome, 
leading to an alternative way for synthesis a step inhibit by a particular antibiotic—one 
way of resistance to sulfonamides and trimethoprim.  
 
These resistance mechanisms affect the antibiotic action in three main ways; 1; The target site 
may be altered, resulting in a lower affinity for the antibiotic; alternatively, an additional 
target may be synthesized. 2; Altered uptake with decreased permeability of the cell wall or 
pumping out the drug with efflux mechanism. 3; Drug inactivation where enzymes modify or 






Table 5 Mechanism of resistance of commonly prescribed antibiotics. 
Antibiotic, examples Mechanism of resistance 
Altering target Altered uptake Drug inactivation 
Βeta-lactams + + + 
Glycopeptides +   
Aminoglycosides + + + 
Macrolides + + + 
Tetracyclines + +  
Lincosamides +   
Sulfonamides/Trimethoprim + +  
Fluorquinolones +  + 
 
 
2.4.6 Transmissions of resistance between bacteria 
Once a bacterium has acquired a resistance mechanism, its next generation will inherit the 
genes. The resistance can also be transmitted to other bacteria. The new genetic material 
carrying the resistance mechanism is exchanged between bacteria through three main routes, 
summarized in Figure. 5. 
Bacterial transformation includes uptake of free genetic material from the environment and 
its incorporation into the bacterial chromosome. During transduction bacteriophages (viruses 
that infect bacteria) infect a resistant bacterium and incorporate bacterial genetic material in 
new phages that are then able to transfer the resistance genes to another bacterium. Finally, 
conjugation implies that two bacteria conjugate and resistance genetic material, encapsulated 
in plasmids, are transferred from one bacterium to the other.  
 
 
Figure 5 Exchange mechanism of genetic material from one bacterium to the other. Reprint with permission provided by 




    
2.4.7 Resistance of clinical importance 
Every bacterium is resistant to some antibiotics. A group of bacteria causing BSI has been 
identified, requiring special attention: Enterococcus faecium, Staphylococcus aureus, 
Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and 
Enterobacter spp., ESKAPE-pathogens. The ESKAPE pathogens are a group of infectious 
bacteria that have garnered particular attention for their ability to escape or evade standard 
therapies through AMR, and their increasing prevalence in BSI. In the U.S, the ESKAPE 
pathogens contribute to 42.2% of bacterial isolates in BSI, and infected patients have an 
increased length of hospital stays and worse outcomes, compared to non-ESKAPE pathogens. 
(121) These bacteria are of particular significance in hospital-acquired or healthcare-
associated infections. From a paediatric point of view, AMR in Escherichia coli, 
Streptococcus pneumonia and Enterococcus faecalis are also important. (102) 
 
2.4.7.1 MRSA 
After the discovery of penicillin in 1928, penicillin G was available for general use in the U.S 
in the 1940s. In 1948 Staphylococcus aureus started to show resistance to penicillin due to 
production of β-lactamases. In 1959, methicillin was discovered as one of several semi-
synthetic penicillin molecules active against β-lactamase/penicillinase-producing 
Staphylococcus aureus. Shortly after methicillin was introduced, strains of S. aureus acquired 
a gene, mecA-gene, encoding for a penicillin-binding protein (PBP2a). PBP2a have a low 
affinity to penicillin, which abolished antibiotic incorporation in the cell wall. (122) The 
mecA gene is regulated by several factors; one is the presence of methicillin, and other is 
penicillin. Methicillin-resistant Staphylococcus aureus (MRSA) was sporadic in children 
until the 1990s, when endemic community-acquired staphylococcal infections first were 
noticed(123). Staphylococcus aureus is the most frequently isolated gram-positive bacteria 
causing BSI in both adults and children, with the highest incidence rate in infants < 1-year-
old, and older individuals. The incidences are relatively similar from different regions, but the 
proportion of MRSA varies with regions and country (64, 124). In adults the mortality rate of 
MRSA BSI is described to be higher than Methicillin susceptible S. aureus (MSSA). (84) In 
children. mortality in both MSSA and MRSA BSI is low, and MRSA is not a risk factor for 
increased mortality. (125, 126) Endocarditis as a complication of Staphylococcus aureus 
bloodstream infections (SAB) is rare in infants, compared to adults, but together with 
pneumonia is associated with higher mortality. (125, 126)  
  
 Global US Europe Sweden 
MRSA   16.4%(127) 1,9%(127) 
Paediatric data  15%(125), Israel 
13% (126), Australia, NZ 
3.1%(128), Gambia 
19-38%(129, 130) 16.4% (18) 





2.4.7.2 Penicillin-non-susceptible Streptococcus pneumoniae  
Streptococcus pneumoniae has been one of the dominant pathogens in paediatric bacteraemia 
worldwide, with considerable morbidity and mortality. Since the introduction of the 
Pneumococcal conjugate vaccine (PCV) targeting the most prevalent serotypes, the 
incidences of invasive pneumococcal diseases have decreased significantly. However, S. 
pneumoniae still has a substantial burden in paediatric sepsis (75) After the introduction of 
the vaccine, non-vaccine serotypes, rather than vaccine-types cause invasive pneumococcal 
diseases. Whole-genome sequencing studies have revealed how Streptococcus pneumoniae, 
adapted to its environment with changes in virulence beyond serotypes, resulting in the 
invasive capacity of serotypes that were noninvasive before PCV introduction. Antibiotic 
resistance increased in non-vaccine serotypes, causing invasive pneumococcal diseases 
against both erythromycin and penicillin. (132). The mechanism of penicillin resistance 
consists of alterations in the PBPs resulting in a reduced affinity to penicillin and a variable 
spectrum of other β-lactams. The term non-susceptible refers to both susceptible with 
increased exposure (higher dose), and resistant. (127) 
  
 US Europe Sweden 
PNSP  0.1-40%(127) 5.2%(18, 127) 
Paediatric data  20%(133) 13.4% (18)  
 
2.4.7.3 VRE 
Enterococcus spp. BSIs are closely related to healthcare-associated infections, with catheter-
associated UTI, central line associated-BSI, intra-abdominal infections in patients with 
underlying disease, and immunosuppression constituting up to 10% of HAI BSI (134, 135) 
Vancomycin-Resistant Enterococcus faecium (VRE) is associated with an increased risk for 
in-hospital mortality and length of stay. (136) The risk for VRE correlates with exposure to 
vancomycin, fluoroquinolones, and meropenem(137) In children Enterococcus BSIs are 
caused by vancomycin susceptible Enterococcus, and neither mortality nor length of stay 
increases, but risk factors for VRE are similar. (138)  
 
 US Europe Sweden 
VRE 30% (139) 17.3%(127) 1.4% (18, 127) 
Paediatric data   9.0% (18)  
 
2.4.7.4 ESBL 
Extended-spectrum β-lactamase (ESBL) is a group of enzymes conferring resistance to β-
lactams; penicillin, cephalosporins and monobactam, but not carbapenems. Most ESBLs are 
inhibited by a β-lactamase inhibitor (clavulanic acid, tazobactam and sulbactam). β-lactamase 
genes are mostly carried in plasmids, mobile genetic element, with a high ability for 
transmission through bacterial conjugation. The first ESBL-producing strain was identified in 
1983 in Germany and had since then effectively spread all over the world. They are most 
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commonly found in important clinical pathogens, Escherichia coli and Klebsiella 
pneumoniae, but are also found in other gram-negative bacteria, mostly in other 
Enterobacterales (Proteus, Enterobacter spp., Citrobacter Serratia, Salmonella, Shigella, 
Morganella and other Enterobacteriaceae) and also in Pseudomonas and Acinetobacter. 
There are several groups of ESBL enzymes with a difference in activity against different 
pathogens. The different types also have different geographic distribution. The main classes 
of ESBL are listed below. All classes have numerous variants. In clinical microbiology, the 
screening breakpoint to suspect ESBL production is a minimal inhibitory concentration 
(MIC) of >1 mg/L for two third-generation cephalosporins. (122)  
• ESBLA.  
o  CTX-M (cefotaximase) 
o SHV (Sulfhydryl variable) 




• ESBLCARBA, (listed below) 
The proportion of ESBL in Enterobacterales  in children is increasing, but with a 
geographical difference in prevalence. Invasive isolates associated with ESBL have a higher 
multidrug resistance compared to screening isolates. (140, 141) Prior hospitalization, long 
hospital stay, indwelling catheters, and antibiotic use have been described as risk factors in 
adults. In children, the risk factors include a recent visit to a healthcare centre, underlying 
comorbidity, NICU understaffing and poor low hygiene standards. (142, 143) 
 
    Global U.S. Europe Sweden 
ESBL, in invasive isolate  15.1% (127) 8.3% (127) 
Paediatric  
data  
29% (144)South Africa 
66%(145) Neonate, Iran 
67.%(146)Neonates, Taiwan 
87%(147) Neonates, India 













2.4.7.5 Carbapenemase-producing Enterobacterales (CPE) 
Due to the spread of ESBL-containing bacteria, the use of carbapenems has increased, with a 
subsequent increase in carbapenem-resistant Enterobacterales. Carbapenemases are β-
lactamases with the ability to hydrolyse the β-lactam ring in penicillin, most cephalosporins, 
and to varying degrees in carbapenems and monobactams. They were first found in the 90s 
and are mostly found in invasive Klebsiella pneumoniae infections. With high rates of 
incidence in some European countries, Greece reported 63.9% of all invasive Klebsiella 
isolates as Klebsiella pneumoniae carbapenemases (KPC) in 2018, but considerably lower in 
most other European countries (127). There are several classes of carbapenemases,(122)  
• ESBLCARBA 
o Metallo β-lactamases (MBL) 
o Klebsiella pneumoniae carbapenemases (KPC) 
o OXA-48  
Geographic trends in the distribution of carbapenemases in children are described to be 
similar in adult and paediatric population(148).  
 Global US Europe Sweden 
E-coli <1%(149) <0,1%(150) 0.1%(18) <0.1% (127) 
Klebsiella 4%(149) 0.6%(150) 7.5.5% (127) 0.2%(127) 
 
Patient-level risk factor for CPE in children is, as for ESBL, including underlying chronic 
medical condition, invasive medical devices, frequent or prolonged hospitalisations, prior 
antibiotic exposure and travel from endemic regions. (148) 
 
2.5 EMPIRIC ANTIMICROBIAL THERAPY 
2.5.1.1 Antibiotic 
Empiric antibiotic indicates the antimicrobial therapy chosen without knowledge of the 
causing organism. Well-chosen empiric antibiotics should provide a good cover for the most 
suspected pathogens, and consider the local pattern of antimicrobial resistance, and still be as 
narrow in the antibacterial spectrum as possible. 
Of equal importance are pharmacokinetic and pharmacodynamic (PK-PD) consideration. 
What does the body do with the drug (PK)? What does the drug do to body (PD)? 
Pharmacokinetics (PK) is the relation between an administrated dose and the achieved 
concentration at the site of infections and comprises absorption, distribution, metabolism, and 
excretion of the drug. PK differ with age; infants have large distribution volume, low protein 
binding and immature renal excretion and metabolism. PK also includes the drug's ability to 
passage over membranes and barriers to the site of the infection, together PK properties affect 
the amount and administrations interval of dosing. 
Pharmacodynamics (PD) describes the relationship between antimicrobial concentration and 
its killing effect. It includes the drug's mechanism of action. Only the free fraction, 
nonprotein bounded, part of the drug has an antibacterial effect. The effect varies in three 




• T>MIC - Duration of when a drug concentration remains above the minimum 
inhibitory concentration (MIC).  
- To achieve a killing effect, time over MIC should be >40% of the 
time.  
- Higher concentration does not improve the killing effect. 
- β-lactams, macrolides and lincosamides are examples of antibiotics 




- Maximal drug concentration over MIC 
- The higher peak concentration, the higher killing effect but also 
increased risk for toxicity. 
- To achieve killing the concentration should be 2-4 times MIC for 
effective killing. 
- Aminoglycosides, have this concentration-dependent killing. 
• AUC/MIC - Area under the serum concentration-time Curve. 
- A combination of time and concentration dependent killing.  
- The killing is correlated to time during 24 hours that remains over 
MIC. 
- Glycopetides, quinolones, linezolid belong to this group 
 
2.5.1.2 Early aggressive vs Watchful waiting 
Febrile infants less than 3 months of age have the highest risk for serious bacterial infection 
and BSI. The risk is inversely correlated with age, with up to 20% of those < 1 month of age 
with fever without an identified clinical source, have a serious bacterial infection. (151). One 
important question is if all children below a certain age ought to undergo a full septic workup 
and be admitted with early aggressive therapy for a possible severe infection, or if there is an 
opportunity for select low-risk cases in the high-risk population. Strategies for identification 
of those with high risk for a possible severe infection has been scrutinised in several studies, 
and different decision trees have been validated. (152-155) It seems that with a thorough 
clinical examination, a blood test with one, or a combination of the inflammatory parameters 
CRP and PCT, urine analysis, the probability to exclude a severe infection is high. 
A low probability for a severe infection could promote a watchful waiting strategy and a 
possibility to withhold antibiotic therapy instead of early aggressive empiric therapy. To 
adapt a watchful waiting strategy, it is critical to facilitate serial clinical and laboratory 
assessment among well-appearing infants, also infants < 1 month of age. A watchful waiting 




2.6 PREVENTION OF BLOODSTREAM INFECTIONS 
2.6.1.1 Vaccination 
Immunisation against pathogens that cause the most prevalent and severe infections is an 
effective way to decrease morbidity and mortality. Before the introduction of Haemophilus 
influenzae type B (HiB) vaccine, the global burden of HiB infections was enormous. Severe 
HiB-infections (i.e. meningitis, bacteraemia, pneumonia, epiglottitis, cellulitis, and 
osteoarthritis) contracted approximately 2.2 million children 0–4 years of age yearly, with up 
to 23% mortality depending on the type of infection. The global incidence of HiB-infections 
was approximately 370/100,000 children 0–4 years of age and 31/100,000 HiB meningitis; 
500,000 children died every year just because of HiB infections. (83) The vaccine 
effectiveness was 95%, and in countries with high coverage, the declining effect on the 
burden was magnificent. From a Scandinavian perspective, it reduces HiB meningitis from 
close to 500 cases annually before the immunisation to less than ten cases per year within five 
years after the vaccine was implemented. (82, 158) 
During our study period vaccine against Streptococcus pneumoniae and Neisseria 
meningitidis had been implemented, with a comparative effect for each pathogen. In the U.S 
pneumococcal conjugate vaccine (PCV) reduce S. Pneumoniae bacteraemia with 95% in 
children 3–36 months of age from an incidence of 74.4/100,000 children before to 
3.5/100,000 children 3–36 months of age after the implementation of PCV (Fig. 6a & 6b). 
(55) This induced a decline incidence for all bacteraemia from 97/100,000 children before to 
21/100,000 after PCV. The drop in incidence resulted in reduced risk bacteraemia from up to 
5% to less than 0.5% for a child 3–36 months of age visiting the emergency department 
because of fever in setting with high PCV coverage. (69) Universal coverage with the 
pneumococcal conjugate vaccine to children is estimated to avert up to 11.4 million days 
/year of antibiotics for pneumonia caused by Streptococcus pneumoniae in children under 
five years of age, a 47% reduction in days of antibiotics. (159)  
 
 
Figure 6a Rate of all bacteraemia by organism per 100 000 
children per year between 1998 and 2014  
 
 
In Sweden incidence for invasive pneumococcal disease (IPD) (including positive culture 
from blood, from cerebrospinal fluid and other sterile fluids) declined from 28.4/100,000 
children 0–2 years of age to 4.3/100,000 after vaccine introduction, and for bacteraemia from 
Figure 6b Relative incidence of bacteraemia by organism 
per study period (pre-PCV7, post-PCV7/pre-PCV13, and 
post-PCV13) Printed with permission 
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6.3 to 2.0/100,000 children 0–2 years of age (160). For unknown reasons N. meningitidis is 
rare in Sweden but is still life-threatening for those contracted with invasive infection. The 
mortality rates are reported to be 5-10%. In countries with higher incidence, vaccines have 
been implemented. In the U.K the hospital admissions of N meningitidis infection decrease 
by 66% after the introduction of the meningococcal serogroup C vaccine, from 34.5 
admission/ 100,000 children in 1999 to 12.4 /100,000 children in 2011. (61)  
 
2.6.1.2 Prophylaxis to identified risk groups 
Streptococcus agalactiae (GBS) emerged as the leading cause of new-born infection in the 
U.S. the 1970s. In the 1980s, clinical trials demonstrated that giving intrapartum intravenous 
ampicillin or penicillin to mothers at risk was highly effective at preventing invasive GBS 
disease in the first week of life (early-onset). Systematic review and meta-analysis found a 
risk of EOGBS of 1.1% (95% CI, .7%–1.6%) for new-borns born to women colonised with 
GBS in pregnancy without a policy of providing IAP for positive GBS screening. As IAP 
coverage increased the risk of EOGBS decreased, with a linear relationship.(76) The risk 
reduction ranged from 40–79% after implementation of IAP, with the most prevalent 
reduction in setting with high coverage of microbiological-screening-based IAP policy.(161) 
In Sweden, a risk-based IAP program was implemented in 2008. 
 
Invasive fungal infections account for 10 % of all cases of late-onset invasive infection in 
very low birth weight (VLBW) infants. (162) Antifungal prophylaxis with intravenous 
fluconazole is proven to be effective for the prevention of invasive candida infection in 
VLBW and ELBW neonates.(163-165) Oral nystatin has been evaluated as effective as 
fluconazole in reducing invasive fungal infection in VLBW neonates. Still, these results have 
been interpreted as uncertain and larger, higher quality trials are recommended by Cochrane, 
to resolve this uncertainty. (166) 
Invasive fungal infection is also a problem for paediatric patients with cancer and those 
undergoing haematopoietic stem cell transplantation. Evidence for antifungal prophylaxis in 
children is lacking but recommended for children undergoing haematopoietic stem cell 
transplantation, acute myeloid leukaemia/myelodysplastic syndrome and relapsed acute 














3.1 GENERAL AIMS 
The general aims of this thesis were to describe the aetiology, risk factors, and occurrence of 
bacteria resistant to antimicrobial therapy in children with bloodstream infections. 
3.2 SPECIFIC AIMS 
3.2.1 Paper I  
To study the occurrence and aetiology of BSI in children aged 0–17 years, and to describe the 
influence of age and underlying comorbidity. 
3.2.2 Paper II 
To study the effect of introducing immunisation against Streptococcus pneumoniae on the 
occurrence of BSI, and the implementation of a risk-based strategy with intrapartal antibiotic 
prophylaxis targeting early-onset sepsis caused by Streptococcus agalactiae 
3.2.3 Paper III 
To evaluate the quantity and quality of antimicrobial prescriptions at our hospital with an aim 
to identify targets to improve the quality and reduce the quantity of antimicrobial use. 
3.2.4 Paper IV 
To study changes in aetiology and incidence of BSI over a 20-year period. Implementations 
of preventive measures and changes in patients mix for hospital admitted patients are 
hypothesised to result in change with implication for designing empiric antibiotic therapy 
regimes, and for the planning of targeted measures to improve therapy and preventions of 
BSI. 
3.2.5 Paper V  
To study the occurrence and trends of antimicrobial resistance and antibiotic prescription in 












 MATERIAL AND METHODS 
 
4.1 STUDY SUBJECTS AND METHODS 
4.1.1 Paper I 
4.1.1.1 Patients and study design 
The study was a retrospective, single-centre descriptive analysis. We included all children 
aged 0–17 years, with positive blood cultures, admitted to Astrid Lindgren Children’s 
Hospital between July 1, 1998, and June 30, 2008. The Hospital serves a primary paediatric 
population of 220,000 children in northern Stockholm and is the regional centre for cancer 
treatment, paediatric surgery, and intensive care serving 440,000 children. Patient identity in 
children with positive blood cultures was obtained from the laboratory information system 
(LIS). Information regarding comorbidity, focal sites of infection, paediatric intensive care 
unit admission, and mortality was retrieved from the hospital records. 
4.1.1.2 Definitions and inclusion criteria 
An episode of bloodstream infection was defined as the presence of an accepted pathogen 
isolated in blood culture, associated with clinical signs of infection. If the same pathogen was 
found in another sample taken 14 days after the previous sample, or if any other species were 
isolated on any other day, those isolates were considered to represent a separate episode. If 
the clinical pictures were not associated with infection or a targeted antimicrobial treatment 
was not prescribed, the recognised pathogen was regarded as contaminants or transient 
bacteraemia, not requiring treatment, and not included in the study. According to the CDC 
criterion, two or more positive blood cultures are required to include possible contaminants. 
In children, two blood cultures are rarely drawn before the start of antibiotic therapy. Possible 
contaminants like Coagulase-negative staphylococci (CoNS) viridans streptococci, Bacillus 
species, Propionibacterium, Corynebacterium, and Micrococcus species were therefore 
considered not-accepted pathogen and not included. 
 The children were categorised into three groups: (i) No underlying comorbidities, (ii) 
underlying comorbidities, including children with cancer, malformation, chronic diseases, 
and immune deficiency, and (iii) children at the neonatal unit. Children in this group were 
admitted shortly after birth to the neonatal care unit and had never been discharged from 
Hospital. 
4.1.1.3 Microbiological methods 
From each patient, 1–2 BacT/Alert P.F. paediatric FAN bottles (BioMérieux, Marcy l’Etoile, 
France) were drawn. Following transport to the laboratory, the bottles were monitored with 
the BacT/Alert 3D-blood culture system (BioMérieux). Any bottle with a positive signal was 
immediately removed from the system, and an aliquot was taken for gram staining and 
subculture, whereas susceptibility testing was performed with disc diffusion according to the 
recommendations from the Swedish Reference Group for Antibiotics. 
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4.1.2 Paper II 
4.1.2.1 Patients and study design 
The study was a retrospective review of all positive blood culture results during two five-year 
periods July 1, 2002–June 30, 2007, and July 1, 2008–June 30, 2013. Conjugated 
pneumococcal vaccination was introduced in the National Swedish Immunisation program in 
the Stockholm area in 2007, the same year when pneumococcal vaccine was introduced. The 
immunisation program started with a 7-valent vaccine but was replaced by a 13-valent 
vaccine in 2010. According to the recommendation from the National Board of Health and 
Welfare, a risk-based program to reduce early neonatal infections of Streptococcus agalactiae 
was implemented nationwide in 2008, according to recommendations from The National 
Board of Health and Welfare. As the new routines were gradually implemented, data from the 
year July 2007 to June 2008 were excluded. Blood culture results, patient identity and patient 
data was retrieved, as in paper one. 
Definition, inclusions criteria and microbiological methods were similar to those in Paper I 
and not further described. 
4.1.3 Paper III 
4.1.3.1 Patients and study design  
The study was a one-day, hospital-wide, point-prevalence survey conducted eight times 
between 2003 and 2017 at Astrid Lindgren Children’s Hospital. For appropriate comparison 
between years, the surveys were performed within three weeks from the second half of 
November to the first week of December. The first five surveys performed between 2003 and 
2010 were a part of a nationwide hospital point-prevalence survey initiated by the Swedish 
Strategic Program against Antibiotic Resistance (STRAMA) and included children and adults 
but did not include patients at the neonatal wards. The retrieved data were reported following 
a standardised protocol developed by STRAMA. The surveys in 2015 and 2016 were a local 
initiative using the same protocol as in the first five surveys. In the last survey in 2017, the 
data retrieved was reported in a similar, but new protocol developed by the Antibiotic 
Resistance and Prescribing in European Children (ARPEC) project. All inpatients admitted at 
8:00 AM were included in the survey, and in children with ongoing antimicrobial therapy, the 
data were collected through chart review. 
4.1.3.2 Patient data 
According to the protocols, information about age, sex, underlying diseases, antimicrobial 
regimen, administered single-unit dose, the number of doses per 24 hours, route of 
administration, indications (community-acquired, hospital-acquired or prophylaxis), and 
diagnosis for treatment were collected. Underlying diseases were defined as a chronic 
condition with increased risk of infections such as cancer, malformation, and immune 
deficiency. In the surveys, 2003–2016 treatment was evaluated as appropriate or 
inappropriate. Incorrect dosing, choice of drug or other faults were evaluated as incorrect. In 
the 2017 surveys, compliance to local or national guidelines was evaluated as appropriate. 
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4.1.3.3 Classification of Antimicrobial Agents 
Antimicrobial agents were classified according to the Anatomical Therapeutic Chemical 
(ATC) Classification System of the World Health Organization. The following antimicrobials 
agents were included in the study; antibacterial for systemic use (J01), antimycotics and 
antifungals for systemic use (J02 and D01BA02), drugs for the treatment of tuberculosis 
(J04A), antivirals for systemic use (J05), antibiotics used as intestinal anti-infectives 
(A07AA) and antiprotozoals used as antibacterial agents (P01AB). 
4.1.4 Paper IV 
4.1.4.1 Patients and study design  
The study was a continuation of the review of BSI initiated in paper I. In this study, we 
retrospectively analysed all blood cultures obtained from patients between July 1998 and 
June 2018 at Astrid Lindgren Children’s Hospital, Karolinska University Hospital. Blood 
cultures were obtained from children with clinical signs of infections, and with a suspicion of 
a serious infection. Results from the blood cultures were retrieved yearly since 1999. In this 
study, definitions, inclusion criteria, and microbiological methods were similar to those in 
Paper I. During the study period, the number of children aged <18 increased from 387,000 to 
510,000 in Stockholm County, which is the population base for oncology and surgery 
patients, and from 198,000 to 255,000 in Northern Stockholm, which is the catchment area of 
the hospital for most other paediatric conditions. Additionally, the number of live births 
increased from 10,800 to 15,500 per year in Northern Stockholm. 
4.1.5 Paper V 
4.1.5.1 Patients and study design 
The study was a retrospective analysis of the occurrence of isolates with acquired AMR in 
children with BSI admitted at Astrid Lindgren Children’s hospital between July 1998 and 
June 2018. Results from blood cultures and patient information were retrieved as in paper I, II 
and IV. 
4.1.5.2 Antibiotic susceptibility testing  
Susceptibility testing was performed with disk diffusion, and the results were reported as 
“resistant” (R) or “susceptible, increased exposure” (I). For gram-positive bacteria, we 
reported S. aureus, resistant to methicillin and lincosamides; S. pneumoniae resistant to 
macrolides, lincosamides, and penicillin non-susceptibility; S. agalactiae resistant to 
macrolides; Enterococcus faecium resistant to vancomycin, and E. faecalis resistant to 
ampicillin. For gram-negatives bacteria, we reported E. coli, Klebsiella, and other 
Enterobacteriaceae, resistant to third generation cephalosporins, trimethoprim-
sulfamethoxazole, aminoglycosides, and carbapenems. We also reported Acinetobacter spp, 
resistant to carbapenems, fluoroquinolones, aminoglycosides, trimethoprim-
sulfamethoxazole; and P. aeruginosa, resistant to ceftazidime, carbapenems, 
aminoglycosides, piperacillin-tazobactam, and fluoroquinolones. Susceptibility for 
antifungals was not evaluated, and Candida spp. were, therefore, not included in the 
denominator when calculating the crude prevalence of AMR. 
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4.1.5.3 Acquisition of reference data 
To compare our collected data with existing data on antimicrobial susceptibility, we retrieved 
reference data from the European Antimicrobial Resistance Surveillance Network (EARS-
Net), the Antibiotic Resistance and Prescribing in European Children (ARPEC) project, and 
the Swedish Surveillance of Antibiotic Resistance (SVEBAR). EARS-Net are based on 
routine clinical antimicrobial susceptibility data on invasive isolates from local and clinical 
laboratories reported to ECDC by appointed representatives from the E.U. member states. We 
retrieved data from the annual report on surveillance of antimicrobial resistance in Europe, 
2018. SVEBAR is a platform that collects daily reports from the local and national network 
of microbiology laboratories. Susceptibility data on invasive isolates from selected pathogens 
are collected, and accessible from the Swedish Agency for Public Health’s website. We 




Paper I. To compare the proportion of Staphylococcus aureus and Streptococcus 
pneumoniae in children with no underlying comorbidity, a comparison of categorical 
variables was performed using Fisher exact test and chi-square test, using the GraphPad 
software (GraphPad Software, Inc, CA, USA). The annual BSI incidence rate in children 
was calculated by dividing the number of children with BSI (numerator) by the total 
number children of the same age strata (denominator). For infants, the number with BSI 
incidences was divided by the total number of live-born children for that year. 
Paper II. Incidence rates were calculated using the same formula as in paper I. To assess 
significant differences between the proportion in the two five-year periods, we used chi-
square test for exact Clopper-Pearson binomial 95% confidence intervals (CI), or exact 
Poisson confidence intervals, to obtain a confidence interval for the outcome. 
Paper III. Trends in CAI, HAI and prophylaxis proportions, the total number of 
antimicrobial prescriptions, the proportion of patients receiving antimicrobial treatment, 
and the proportion of patients with an underlying disease were analysed with non-
parametric Mann-Kendall test, using the function cor.test in R version 3.5.0. (R Core Team. 
A language and environment for statistical Computing; 2018. Vienna, Austria: R 
Foundation for Statistical Computing; 2018. Available at: http://www.R-project.org).  
Paper IV. Trends of incidence and proportions were tested using the Kendall tau rank 
correlation. The correlation was assessed as weak, moderate, or strong, depending on the 
tau (τ) value. τ varies from 1 to -1, and a value of 0 (zero) is interpreted as no monotone 
trend, negative values as a negative trend and positive values as a positive trend. The 
statistical significance level was set at p < .05. The annual BSI incidence in infants was 
calculated by dividing the number of children with BSI (numerator) with the total number 
of live-born children in Stockholm for that year (denominator). For older children, the total 
number of children with BSI was divided by the total number for the same age strata for 




Paper V. Difference in the occurrence of AMR percentages between HAI vs CAI and in 
children before vs after one year of life were compared using a chi-square test. A p-value of 
less than 0.05 indicated statistically significant differences. Trends for the occurrence of 
acquired AMR and the consumption of antimicrobials in hospitals over the study period for 
different paediatric risk groups were tested with the Kendall tau rank correlations test. 
 
 
4.3 ETHICAL CONSIDERATIONS 
Approval for the studies reported in all papers was obtained from the Regional Ethical 
Review Board at Karolinska Institutet, Stockholm 
For Paper I; Dnr 2009/1063-31/2  
For Paper II; Dnr 2013/2056-32 
For Paper III; Dnr 2018/2069-32 
For Paper IV; Dnr 2013/2056-32, 2018/2069-32 
For Paper V; Dnr 2019-05049, 2009/1063-31/2 and 2013/2056-32 
The studies are retrospective register studies and spans over a long period. It was not 
considered reasonable, or feasible, to obtain approval from each individual who participated 





Our main findings were: 
• Age and risk factors correlate with BSI incidence.  
• Age and risk factors correlate with the aetiology of BSI. 
• Immunisation against Streptococcus pneumoniae is effective. 
• Intrapartal antibiotic prophylaxis reduces the early onset of GBS BSI. 
• A high proportion of hospitalised patients receive antimicrobial therapy. 
• Rates of antimicrobial resistance are low, but there is an alarming increase in some 
of the most prevalent pathogens. 
• Aetiology of BSI changes over time and needs continuous and long-term 
surveillance. 
 
5.1 AGE AND CONCOMITANT RISK FACTORS INFLUENCE THE INCIDENCE 
OF BSI 
In paper I, II and IV, 66,698 blood cultures retrieved from children with clinical signs of 
infections between July 01, 1998, and June 30, 2018, were analysed. As described in the 
materials and methods section, we decided to exclude coagulase-negative staphylococci 
(CoNS) as a possible contaminant. The rationale behind this exclusion was that two blood 
cultures were rarely drawn before starting antibiotic treatment in children. The lack of two 
blood cultures makes it impossible to include contaminants, according to the CDC’s 
definition for possible contaminants. The number of retrieved and analysed blood
cultures are presented in Figure 7. The 
majority of cultures were negative (83%; 
55,590/66,986). Of the 11,396 positive 
cultures, 9317 were considered as possible 
contaminants, and thus excluded. In the 
end, 2079 or 3.1% of all retrieved blood 
cultures were positive and further analysed  
 





During the preparation of paper I, we identified four different groups of children with 
different distribution of pathogens and different risk for BSI. 
 
• Newborn children warded at the neonatal ward 
• Oncology patients 
• Children with different underlying co-morbidity  
• Previously healthy children with no underlying co-morbidity  
 
 Each category compromise approximately 25% of the total BSI episodes, Figure 8. Although 
we hypothesized that the proportion of previously healthy children would gradually decrease, 
they continue to constitute 25% of the individuals. The number children in each group vary, 
from the small group of approximately hundred diagnosed oncology per year to the whole 
paediatric population in our catchment area who also constitutes the population at risk for 
children with no underlying co-morbidity. 
 
 
Figure 8 Proportion of BSI for each risk groups 
 
 
In paper I, II and IV, we estimated BSI incidence in different age groups, but with some 
difference in age stratification. We also separated children, 0–2 months old, warded at the 
neonatal units, from the same age group not warded at neonatal units. The estimated 
incidences are presented in Figure 9. 
The crude BSI incidence was 25.5/100,000 in children aged 0–17 years. Children 0–2 months 
old accounted for 34.4% (715/2079) of all children. A majority of children with BSI (64.1%; 
458/715) aged 0–2 months, were admitted to neonatal wards, equalising an estimated 
incidence of 1.8/1,000 live births. Among children with BSI at the neonatal wards, 74.7% 
were born before gestational week 33. For 0–2 months old children warded outside neonatal 
wards, there was a 58% lower incidence, 0.7/1,000 live births children, which included both 
children with various underlying co-morbidity and children with no underlying co-morbidity. 
For a 0–2 months old child with no underlying co-morbidity, the estimated incidence for BSI 
was 0.4/1,000 live births. After the neonatal period, BSI incidence was 47.5/100,000 for 
children aged between 3 months and 2 years, and 15/100,000 for children and adolescents 
aged between 3 and 17 years. BSI risk was highest in children at the neonatal wards, followed 























































































































Figure 9 The estimated incidence of BSI for different age groups.  
 
 
 During the entire observation period, BSI incidence decreased, which was most evident in 
children aged between 3 months to 2 years (τ= -0.59, P =0.0006), and in neonates with early-
onset BSI (τ= -0.44, P =0.0069). Comparing the first 10 years to the last 10 years of the 
study, the mean decline in BSI incidence in children warded at the neonatal wards was 29%, 
from 2.09/1,000 to 1.48/1,000 live births. For children 0–2 months old, warded outside 
neonatal wards, BSI incidence did not change. For children 3 months to 2 years old, BSI 
incidence declined 30%, from 0.53/1,000 to 0.37/1,000 children from the first to last ten years 
of the study period. This decrease explained the overall decrease for BSI in children aged 
between 0 and 17 years. 
 
In conclusion, the risk for BSI inversely correlated with age, with a highest risk for the 
youngest individuals. Patients with cancer had the highest risk for BSI, but data of the total 
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5.2 THE AETIOLOGY OF BSI IS INFLUENCED BY AGE AND CONCOMITANT 
RISK FACTORS 
 
The aetiology of BSI varies considerably, both with age and underlying risk factors, as shown 
in paper I, II and IV. Therefore, data representing previously healthy children will be 
separated from children with known risk factors for BSI. Regardless of age and underlying 
risk factors, Staphylococcus aureus was the most common pathogen. All positive cultures are 
presented in table 6.  
 




Oncology patients Patients with 
underlying co-
morbidities* 
Patients at neonatal 
wards 
Pathogen n,  (%)  n, (%) n, (%) n, (%) n, (%) 
S. aureus 657 (31,6)  184 (33,5) 127  (26,3)  209 (35,9) 137 (29,5) 
S. pneumoniae 178 (8,6)  113 (20,5) 25  (5,2)  38 (6,5) 2 (0,4) 
Enterococcus spp. 194 (9,3) 14 (2,5) 66  (13,7)  65 (11,2) 49 (10,5) 
S. pyogenes 58 (2,8)  36 (6,5) 6  (1,2)  15 (2,6) 1 (0,2) 
S. agalactiae 114 (5,5)  38 (6,9) 4  (0,8)  9 (1,5) 63 (13,5) 
L. monocytes 4 (0,2)   0,0 2  (0,4)  1 (0,2) 1 (0,2) 
Other gram-positive bacteria 37 (1,8)  10 (1,8) 12  (2,5)  12 (2,1) 3 (0,6) 
Gram positives, total 1242 (59,7)  395 (71,8) 242  (50,2)  349 (60,0) 256 (55,1) 
E. coli 217 (10,4)  56 (10,2) 53  (11,0)  51 (8,8) 57 (12,3) 
Klebsiella spp. 123 (5,9)  4 (0,7) 47  (9,8)  41 (7,0) 31 (6,7) 
Other Enterobacteriaceae 121 (5,8)  3 (0,5) 34  (7,1)  46 (7,9) 38 (8,2) 
P. aeruginosa 86 (4,1)  1 (0,2) 42  (8,7)  28 (4,8) 15 (3,2) 
N. meningitides 20 (1,0)  18 (3,3)   (0,0)  2 (0,3)  (0,0) 
Other gram-negative bacteria 120 (5,8)  31 (5,6) 39  (8,1)  33 (5,7) 16 (3,4) 
Salmonella 48 (2,3)  41 (7,5) 5  (1,0)  3 (0,5)  (0,0) 
Gram negatives, total 735 (35,4)  154 (28,0) 220  (45,6)  204 (35,1) 157 (33,8) 
Candida spp. 102 (4,9)  1 (0,2) 20  (4,1)  29 (5,0) 52 (11,2) 


















5.2.1  Aetiology in previously healthy children 
For previously healthy children, the six most prevalent pathogens that accounted for 85% of 
all BSI episodes, with marked age-dependent variability, are shown in Figure 10. Over 80% 
of episodes were associated with signs of focal infection; meningitis for Streptococcus 
agalactiae, pneumonia and meningitis for Streptococcus pneumoniae, urinary tract infections 
for Escherichia coli, skin- and soft tissue infections or bone- and joint infection for 
Staphylococcus aureus, and respiratory tract infections for Streptococcus pyogenes. 
The remaining 15% of BSI incidences comprised of a variety of bacteria; 20 episodes of 
Neisseria meningitidis, 19 episodes of Haemophilus influenzae pathogens (of whom one type 
B with fatal outcome and the rest non-typeable); eight episodes of Fusobacterium 
necrophorum with Lemierre’s syndrome, and few episodes of other gram-negative bacteria, 
and Enterobacteriaceae, Enterococcus faecalis and other gram-positive bacteria. In 
conclusion, previously healthy children had a limited spectrum of well-known pathogens and 
for an unknown reason a low occurrence of N. meningitidis. 
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5.2.2 Aetiology in children with underlying co-morbidity and oncology 
patients 
In children with underlying co-morbidities, BSI was more common, with a fever of unknown 
origin. There was no apparent age-dependent variation. Staphylococcus aureus was the 
dominant pathogen, present in 30% of all episodes, in all age groups. S. aureus infection in 
this category appeared as fever without focus and was associated with intravascular catheters. 
After S. aureus, the most prevalent isolates were Enterococcus faecalis and faecium, E. coli, 
Klebsiella spp, other Enterobacteriaceae and other gram-negative bacteria. Isolates of 
Acinetobacter baumannii, Stenotrophomonas, Serratia marcescens, and Candida spp. were 
only found in children with severe underlying comorbidity. The occurrence of Acinetobacter 
declined during the latter part of the study, possibly indicating an improved hygiene standard. 
Figure 11 shows the distribution of isolates. Classical paediatric pathogens like Streptococcus 
pneumoniae, Streptococcus pyogenes, and Haemophilus influenzae also occurred, but to a 

























































5.2.3 Aetiology in children warded at the neonatal wards 
During early-onset BSI, 50% of all incidences showed a positive bacterial culture within 48 
hours of admission. Streptococcus agalactiae and E. coli were the most commonly isolated 
pathogens and constituted 72.8% of episodes, with S. agalactiae causing 45.6%, and E. coli 
causing 27.2% incidences respectively. All early-onset BSI due to Streptococcus agalactiae 
were culture-positive within 72 hours after births in children warded at the neonatal wards. 
Thereafter, Staphylococcus aureus was the most prevalent isolated pathogen, found in 
approximately 30% of cases. Also, here, Staphylococcus aureus was related to the presence 
of an intravascular catheter. Enterococcus faecalis was common, regardless of time since 
birth. E. coli, Klebsiella, other Enterobacterales, Pseudomonas aeruginosa and Candida 
became more frequently found in patients aged 1 week and beyond. Figure 12 shows the 




Figure 12. The proportion of each pathogen at different age for children warded at the neonatal ward in bars. The line joins 
















































5.2.4 Community-acquired or hospital-acquired infections 
The aetiology for BSI differed considerably between children with the community- or 
hospital-acquired infections, which is related, to an extent, to the underlying co-morbidity and 
risk groups. Children without underlying co-morbidity had a CAI in 97.5% of all BSI 
episodes. S. aureus was the most frequently isolated pathogen for CAIs, and HAIs. In the 
case of CAI, a focal infection with osteomyelitis and septic arthritis was usually found in 
combination with clinical signs. 
In children with underlying co-morbidity and in children at the neonatal units, HAI 
constituted 61.2% and 84.5% respectively. However, the distinction between CAI and HAI in 
children with underlying conditions is unclear and challenging, since neither of them predicts 
which pathogens to expect. Factor like patients’ characteristics and underlying comorbidities 
predict the causative pathogen with higher accuracy than the timing of a positive culture. In 
children with no underlying diseases and neonates, there was a more marked difference 
between HAI and CAI. In Figure 13, the proportion of pathogens in BSI for CAI and HAI for 
different risk groups are presented  
 
 





















































































5.3 PREVENTIVE STRATEGIES TO REDUCE BSI ARE EFFECTIVE 
5.3.1 Immunisation against Streptococcus pneumoniae 
In paper II, we evaluated BSI in relation to universal pneumococcal immunisation in 
children, and it was further analysed in paper IV. Before the introduction of the 
pneumococcal conjugate vaccine (PCV) in 2007, Streptococcus pneumoniae accounted for 
30% of all isolated BSI pathogens in previously healthy children. Overall, BSI with 
Streptococcus pneumoniae declined by 68%, as shown in Figure 14. In children aged 
between 3 and 36 months (the most common age span for contracting S. pneumoniae 
infection); the incidence declined by 71% from 21.7 to 6.3/100,000 children in the ten-year 
study period after the introduction of PCV. The reduction of invasive S. pneumoniae infection 
was also reflected by fewer children presenting with S pneumoniae attributable meningitis, 




Figure 14 The estimated incidence for BSI with Streptococcus pneumoniae. Immunisation was introduced in 2007 
 
5.3.2 Intrapartal antibiotic prophylaxis against Streptococcus agalactiae 
Early-Onset Sepsis 
To prevent early-onset sepsis (EOS) infection by Streptococcus agalactiae (Group B 
streptococcus or GBS), a risk-based Intrapartal Antibiotic prophylaxis Programme (IAP) was 
implemented in Stockholm in 2008. In short, in this programme antibiotic prophylaxis is 
prescribed to women in labour, because of an identified risk of S. agalactiae colonisation, 
since maternal high colonisation rate of S. agalactiae increases the risk of early-onset sepsis 
with S. agalactiae (EOS GBS) in the new-born. 
In paper II, S. agalactiae was identified as the dominant pathogen in severe neonatal 
infections during the first day of life. Our estimated incidence of EOS GBS before IAP 
implementation was 0.31/1,000 live births, which dropped to 0.06/1,000 during the first five 
years after AIP implementation, with only 3 cases between 2009 and 2012. In paper IV, it 
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When the medical records were scrutinised for children with EOSGBS, we observed that 
63% (14/22) of the pregnancy fulfilled criteria for IAP, but only 14.3% (2/14) received IAP. 
 
 
Figure 15 The estimated incidence of early-onset infection. Intrapartal Antibiotic prophylaxis programme was implemented 
in 2008 
5.3.3 Candida prophylaxis 
Besides the changes in early-onset BSI, due to S. agalactiae, in paper II we observed a 
decrease in early-onset BSI with E. coli, other gram-negative bacteria, and gram-positive 
bacteria others than S. aureus. In late-onset BSI (LOS), there was no trend for a changed 
overall incidence. However, BSI with Candida spp. BSI (τ= - 0.58, P= 0.0005) declined 
significantly after the introduction of candida prophylaxis in neonatal units in 2010. Since the 
introduction, only 3 episodes of candidemia were detected in the neonatal units. As opposed 
to the observed decrease for most pathogens during the neonatal period, Staphylococcus 
aureus was more frequently isolated towards the end of the study period, as reported in paper 
IV. In Figure 16, the estimated incidence of late-onset BSI are shown.  
 
Figure 16. The estimated incidence of late-onset infection.  
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5.4 ANTIMICROBIAL THERAPY FOR HOSPITALISED PATIENTS 
In paper III, we evaluated all in-hospital patients who were prescribed antibiotics in eight 
one-day point-prevalence surveys between 2003 to 2017. Overall, 35.5% (336/946) of 
patients received antimicrobial therapy. The top three indications for antimicrobial 
prescription, including sepsis (involving fever with neutropenia and fever of unknown 
origin), respiratory infections and, intra-abdominal infections attribute to 23.6%, 21.1% and 
16.1% of BSI incidence, respectively. During the study period, there was a small increase 
in the number of patients who received antibiotics, but the proportion of patient receiving 
antimicrobials was not significant. The distribution of antimicrobials prescribed for 
treatment of community- and hospital-acquired infections, according to the Anatomical 
Therapeutic Chemical Classification (ATC)-System are presented in Figure 17 as the 
proportion of prescribed antimicrobials for each survey. 
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5.4.1 Trends of antimicrobial therapy 
The results concluded that there was a change in the prescription of antimicrobial therapy 
during 2003–2017. Prescription of third-generation cephalosporines declined concomitantly 
with community-acquired infections and an increase in prophylactic therapy to specific risk 
groups of patients. During the observation period, the total paediatric population in the 
hospital catchment area increased by 24.1%, but the number of hospital beds decreased by 
35.9%, which contributed to a shift in patient mix. We observed an increase in patients with 
underlying comorbidity from 41.2% to 65.3% during the study period (p =0.031). Among 
those patients with underlying co-morbidities, 50% were oncologic patients. 
During the study period, medical prophylaxis against fungal and other opportunistic 
infections in oncology patients and premature, very-low birthweight children, increased. The 
prescription for community-acquired infections decreased significantly, which is partly 
related to a concurrent decrease in BSI incidence due to Streptococcus pneumoniae. 
 
Figure18. Prevalence of antimicrobials prescribed per CAI, HAI, and prophylaxis 
 
In paper V, we also look for a trend in antimicrobial therapy. We included data on delivered 
doses of the most common antimicrobials from 2010 to 2018. There we could not confirm the 
decrease in the use of third generation cephalosporines; the trend was increasing (τ = 0.5, p 
.007) rather than declining. As possible explanations for the different findings could be that 
point-prevalence surveys were conducted at non-representative days and that neonatal 
settings were excluded in the point-prevalence surveys. During the first five point-prevalence 
surveys, the neonatal antimicrobial prescription was excluded from the compiled 
presentation. 
During the period between 2010 and 2018, the total antibiotic use did not change. The use of 
piperacillin with enzyme inhibitor increased (τ = 0.7, p .0048), partly because of a 
recommendation of Piperacillin-Tazobactam in cases of neutropenic fever in favour for 



















5.4.2 Antimicrobial prophylaxis 
In paper III, one finding was the increased use of antimicrobial prophylaxis, mainly to 
oncology patients and surgical prophylaxis. The increase was attributed to medical 
prophylaxis to oncologic patients against fungal and other opportunistic infections. Oncology 
patients receive an overall 24% of all prescribed antimicrobials. Still, during the study period, 
the proportion increase, and in 2017, 48% of all prescribed antibiotics were directed to 
oncology patients (neonatal patients were omitted), with 42% of the prescriptions for medical 
prophylaxis. In Figure 19, the distribution of antimicrobial prophylaxis is presented.  
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5.5 RATES OF ANTIMICROBIAL RESISTANCE  
5.5.1 Prevalence of antimicrobial resistance 
In paper V we evaluated the prevalence of AMR in children n with BSI. AMR was present 
in 9.2% of all BSI isolates and was most prevalent in oncology patients, the patient group that 
also received most antimicrobial therapy. Our rates of AMR from the last five years are 
presented in Table 4, where we also present other paediatric data from Europe, and mixed 
adult and paediatric data from Sweden and Europe. Our prevalence was low compared to 
other European paediatric data, but almost in harmony with Swedish mixed adult and 
paediatric data. 
 Paediatric data  Mixed adult and paediatric data 














Staphylococcus aureus       
  Methicillin-resistance 3.3 16.4  16.4 1.9 2.0 
  Lincosamides 8.4     4.3 
Enterococcus faecalis       
  High-level gentamicin 0.0 30.5  27.1 12.8  
Enterococcus faecium       
  Vancomycin 0.0 8.3  17.3 1.4  
Streptococcus. pneumoniae       
  PC-non-susceptibility 0.0 13.4  10.8 5.5  
  Macrolides 7.1 33.1  15.3 4.5  
Escherichia coli       
  3rd gen. Cephalosporins. 15.5 10.7  15.1 8.3 9.5 
  Aminoglycosides 5.2 13.5  11.1 7.7 7.0 
  Fluoroquinolones 15.5 8.5  25.3 18.1 20.5 
  Carbapenems 0.0 0.0  0.1 <0.1 0.1 
Klebsiella pneumoniae       
  3rd gen. Cephalosporins 11.1 29.9  31.7 5.5 11.5 
  Aminoglycosides 0.0 26.2  22.7 3 6.8 
  Fluoroquinolones 7.4 7.5  31.6 10.1 13.9 
  Carbapenems 0.0 1.9  7.5 0.2 0.3 
Pseudomonas. aeruginosa       
  Pip-tazobactams 8.7 36.0  17.6 7.8  
  Ceftazidime  4.4 25.8  14.8 6.1  
  Aminoglycosides 0.0 27.3  19.3 1.0  
  Fluoroquinolones 4.4 23.4  23.1 7.1  
  Carbapenems 13.1 32.8  20.5 4.4  
Table 7. Comparison of the prevalence of AMR found in our material and European paediatric and adult data and Swedish 
date with mixed adult and paediatric isolates.  
 
5.5.2 Trends 
In paper V, we describe a trend for increased antimicrobial resistance (AMR). The increase 
was significant for both gram-positive and gram-negative isolates. In gram-positive isolates, 
an increase of Staphylococcus aureus resistant to lincosamides and Streptococcus 
pneumoniae resistant to macrolide, tetracycline, and trimethoprim-sulfamethoxazole 
contributed to the increasing BSI trend. During the last period of our study, 13.4% of 
Staphylococcus aureus was found resistant to lincosamides. CAI in previously healthy 
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children comprises a large proportion of AMR in gram-positive bacteria. In gram-negative 
bacteria, 82.7% of isolates were AMR in oncology patients during the last five-years. 
 
Figure 20 Number of Gram-positive (GP) and gram-negative (GN) with isolates express AMR 
5.5.3 ESBL 
The prevalence of extended-spectrum β-lactamase (ESBL) producing Enterobacterales 
increased during the study period and constituted 14.1% of the isolates in the last five-years 
of observation, 15.5% of E. coli and 11.1% of Klebsiella pneumoniae were ESBL-positive. A 
majority (64.7%) of ESBL isolates exhibited resistance to ≥ three classes of antibiotics and 
were, by definition, multidrug-resistant. More than half (52.9%) of ESBL producing 
Enterobacterales were found in children with no previous antibiotic therapy. Hospital-
acquired infection accounted for 58% of cases, whereas 50% were oncologic patients. A high 
number of patients (82.4%) with ESBL had a history of travel, hospital-admission or a 
household member travelling or originated from a non-Nordic country.  
 





14.1% 15.5% 11.1% 64.7% 52.9% 47.1% 82.4% 5.8% 
 
We found higher rates of ESBL than those reported by EARS-net with Swedish data, but our 
rates are similar to the EARS-net European mean rates of E. coli ESBL (15.1%), but lower 
for Klebsiella (31.7%). The mortality rate for children contracted with ESBL producing 
Enterobacterales was 5.8% (1/17), compare to 5.9% mortality in children with BSI with 
susceptible isolates. 
5.5.4 MRSA 
MRSA occurrence was 3.2% of all S. aureus BSI over the entire observation period. MRSA 
also increased and constituted 5.1% of BSI incidences during the last five-years. MRSA 
infection was more common in children without underlying comorbidity, and 75% were 
community-acquired infections. As for ESBL, a high proportion (75%) of affected 
individuals had a history of recent stay, hospital admission or a household member travelling 





The overall aim of the thesis was to describe the aetiology, risk factors, and occurrence of 
bacteria resistant to antimicrobial therapy in children with bloodstream infections (BSI). The 
following scientific question were asked. 
• What is the current prevalence and distribution of BSI in children in our area? 
• Has the incidence of BSI changed during the study period?  
• Is there an aetiological difference in BSI between previously healthy children and 
children with underlying diseases? 
• Can we identify targets for improving antimicrobial prescriptions to hospitalised 
children? 
• How common is AMR among children with BSI? 
 
6.1 STRENGTHS  
Data presented in my thesis is based on the general paediatric population in Stockholm where 
patient information on BSI was collected continuously for over 20 years. Since the hospital 
serves as the primary hospital for approximately 12% of the Swedish paediatric population, 
25 % of the paediatric population with surgical and oncologic conditions, we believe our data 
could be generalized for the total Swedish paediatric population. Our hospital is also a tertiary 
hospital with intensive care units and neonatal intensive care units that gave us the possibility 
to evaluate BSI for a general paediatric population as well a population of children with 
underlying conditions. All longitudinal data ware retrieved by only a few persons which we 
believe make the data-collection similar and comparable over time. This is the first 
characterization of BSI in a paediatric population in Sweden.  
6.2 LIMITATION 
The retrospective study design made it difficult to collect data on patient characteristics in a 
structured way. We depended on the quality of the medical records for our data collection on 
patient risk factors and antibiotic prescription. Data on aetiology and AMR were retrieved 
from the Clinical Microbiology database, which made the data on bacteria more reliable. To 
further analyse risk factors, it would have been appropriate to use a case-control study for 
comparison. Our hospital is a tertiary referral centre that skewed our patient mix to a higher 
occurrence of children with underlying co-morbidity, which could affect the appropriacy of 
generalization. 
 
6.3 THE DISTRIBUTION OF BSI IN CHILDREN IN OUR AREA 
During the preparation of paper I, four different groups of children were identified with 
significant differences in the distribution of pathogens with implications for empiric antibiotic 
therapy regimens as well as for planning targeted measurements to improve therapy and to 
prevent BSI. For this thesis, the following groups were used when analyzing data on 
epidemiology and aetiology of BSI, where each category compromised approximately 25% 
of total BSI episodes 
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• Newborn children warded at the neonatal ward 
• Oncology patients 
• Children with different underlying co-morbidities  
• Previously healthy children with no underlying co-morbidities 
Although we hypothesized that the proportion of previously healthy children with BSI would 
gradually decrease, this was not the case. However, the number of children in each group 
varied, with few children diagnosed with cancer each year (compared to the number of 
newborns), and the paediatric population in our catchment area without underlying co-
morbidity 
6.3.1 Definition of CAI or HAI in our cohort 
In children with no underlying comorbidity, an overwhelming majority (97.5%) of BSI 
episodes were categorized as CAI. These episodes were characterized by a few causative 
pathogens and were often accompanied with focal signs of infection. On the other hand, BSI 
in children warded at neonatal wards were mainly categorised as HAI (84.5%). In children 
with underlying comorbidities and oncology patients, it was more difficult to classify the 
episodes but there were slightly more HAI (61%). 
The distinction we made between CAI and HAI in children with underlying conditions may 
not be entirely appropriate. The classification system does not recognize the healthcare-
associated infections that emerged in patients with complex conditions over the study period. 
These children and their episodes of BSI are managed as cases ranging between HAI and 
CAI. Our results, similar to other groups’, reveal that only a few pathogenic infections can be 
categorized as CAI or HAI, with infections from Streptococcus pneumoniae, Streptococcus 
pyogenes, Salmonella spp., and Neisseria meningitidis predominantly appearing as CAI, and 
those from Enterococcus spp. as HAI. (96, 169) The timing of positive blood culture results, 
relative to hospital admissions, is insufficient to differentiate the aetiology of BSI. Typically, 
HAI pathogens are frequently isolated from samples taken within 48 hours after 
hospitalization. (96, 169) Patient’s clinical characteristics, recent healthcare exposure, and 
recent invasive procedures could predict the possible pathogens with higher accuracy. This 
knowledge is important while taking an informed decision about empiric therapy. 
The healthcare-associated infections (HCAI) category has been introduced to consider the 
patient’s characteristics appropriately. The HCAI definition includes BSI in association with, 
a) occurrence of an indwelling medical device, b) surgery within 30 days, c) invasive 
instrumentation or incisions perform within 48 hours of the onset of symptoms, and, d) 
neutropenia induced by cytotoxic therapy (170) 
 
6.4 OVERALL INCIDENCE OF BSI 
We concluded that the incidence of BSI varies considerably with age. Prematurely born 
children have, by far, the highest incidence rate; tenfold higher than in children born after the 
neonatal age. 
Overall, the incidence decreased slightly for the whole age span of 0–17 years. However, for 
two groups, the decline was more pronounced. In children 3 months–2 years of age, the group 
with the highest risk for pneumococcal diseases, the incidence of BSI decreased after the 
introduction of the conjugated pneumococcal vaccine (PCV) in 2007 has declined to below 
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0.5/1,000 children. A similar decrease is reported from both the U.S and Europe, and the rates 
for bacteraemia is <0.5% in feverish children 3–36 months of age presenting to the 
emergency department in areas with high PCV coverage. (69) 
For neonates, the incidence of GBS EOS decreased after the implementation of a risk-based 
intrapartal antibiotic prophylaxis in 2008. In the U.S., IAP has been used since 1996, and it 
has reduced GBS EOS by 80%. Screening based IAP is in the U.S now recommended in 
favour of a risk-based screening (161) Moreover, BSI due to candida almost disappeared after 
the introduction of candida prophylaxis to very-low birth weight premature children. Taken 
together this led to 
• 29% decrease in BSI in children 0–2 months of age between the first and last ten 
years of the study 
• 30% decrease in BSI in children 3 months–2 years of age. 
 
This finding contrasts with international studies on paediatric sepsis based on diagnosis 
codes, that have reported an increase in prevalence. (34, 35) (37, 38) These studies report an 
increase in sepsis and also describe a temporal correlation of a decline in mortality. (34, 35, 
38) Although somewhat confusing, sepsis occurs because of several reasons other than BSI, 
which may impact both prevalence and mortality. The clinical definition of sepsis includes 
serious bacterial infections but does not require a positive blood culture. Sepsis also includes 
some severe viral infections and inflammatory conditions that could be life-threatening 
without accessibility to healthcare facilities but with near null in-hospital-mortality. Thus, 
when comparing studies that utilized different definitions for sepsis, we observed up to a 
tenfold difference in both the prevalence and mortality due to sepsis. A more uniform 
definition of paediatric sepsis would facilitate comparison between studies conducted in 
different parts of the world. 
 
6.4.1 High and low-risk neonates 
In paper I and IV, we concluded that new-born children warded at neonatal units have the 
highest incidence of BSI, despite the decreasing trend over the study period. Our finding of 
an estimated incidence of 1.46/1,000 live births is similar to a previously published Swedish 
report (171) that estimated an incidence rate of 1.2/1,000 new-born (when CoNS was 
excluded). For neonates admitted for BSI outside the neonatal units, the incidence was 
0.41/1,000 live births, similar to the incidence rate of 0.37/1,000 in children 3 months to 2 
years of age. This finding is consistent with other reports where community-acquired late-
onset BSI is reported to be considerably lower for neonates outside the neonatal units than for 
the high-risk group of premature neonates warded at neonatal wards. (92) There is also 
evidence for a declining risk for invasive infections during the first month of life, with an 
89% lower risk for invasive infections at week four compared to week one.(172) This may 
support a strategy of watchful waiting with serial clinical and laboratory assessments in the 
full-term infant, rather than aggressive early antimicrobial therapy for suspected sepsis. (156) 
Contrasting to adopting such a strategy there are other studies recommending empiric 
antibiotic therapy in all febrile children <21 days of age with fever duration less than 6 hours. 
regardless of their general appearance or blood test results. For children >21 days of age, with 
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good appearance and normal blood test result, it was possible to rule out invasive bacterial 
infection with high sensitivity. (173) 
 
6.5 AETIOLOGY PATTERNS CHANGE OVER TIME  
During the study period, we observed some important changes in the aetiology of BSI. On the 
one hand, changes correlate to the decreased incidence of BSI described above and relates to 
different targeted measures, also described above. On the other hand, the changes correlated 
to a change in patient composition. 
6.5.1  A decline in the occurrence of Streptococcus pneumoniae 
BSI due to Streptococcus pneumoniae declined by 71% among children 3–36 months of age, 
which was previously a high-risk age-group for severe S. pneumoniae infections during 
childhood. The decline was a result of the introduction of the pneumococcal conjugate 
vaccination (PCV) in the National Swedish Immunisation program. The same decline has 
been described extensively from other countries that implemented the immunisation 
programme. (56) (174, 175) The lower burden of S. pneumoniae infections also causes fewer 
fatalities. This was reflected by fewer children presenting with meningitis attributed to S. 
pneumoniae. (176)  
In addition to the individual benefit of immunisation, the vaccines also have an impact on 
antimicrobial use and antibiotic resistance. A universal cover with a pneumococcal conjugate 
vaccine is estimated to contribute to a large (47%) reduction of days on antibiotics per year 
for pneumonia caused by S. pneumoniae in children < 5 years. (159) Consequently, a reduced 
burden of invasive pneumococcal disease (IPD) and reduced antimicrobial use could result in 
a decline in penicillin non-susceptible strains of S. pneumoniae, and perhaps also less 
resistance to erythromycin. (175) However, as reported from Sweden, a rise of AMR in IPD 
disease with non-vaccine serotypes is observed. (177) The current PCV immunisation leads 
to an expansion of non-vaccine serotypes, and cases of IPD after PCV introduction, caused 
by non-vaccines ST, are rising in Sweden. (160) However, the incidence of IPD is still much 
lower than before PCV, but increase in non PCV serotypes may increase and potentially 
compromise the benefits of the vaccine. (178) Thus Streptococcus pneumoniae remains a 
significant pathogen and should still be considered in paediatric BSI. 
6.5.2 Early-onset sepsis due to Streptococcus agalactiae decline  
Risk-based intrapartal antibiotic prophylaxis (IAP), where antibiotics directed to women in 
labour with a known risk for high-grade vaginal colonisation of S. agalactiae, reduced the 
risk for GBS EOS from 0.31/1,000 live births to 0.06/1,000 live births in the five first year 
after its implementation in 2008 (paper II). In a meta-analysis concerning the use of any 
intrapartum antibiotic prophylaxis, the incidence of GBS EOS was 0.23 /1,000 live births 
(95% CI 0.13–0.59). (179) However, when we extended the study period in paper IV, the 
incidence returned to 0.26/1,000 live births. The reason for this throwback is not apparent, 
but we speculate that it is due to decline in adherence to the IAP guidelines in the last period 
of our study. Even optimal adherence to either IAP strategy is estimated to reduce the 
incidence of 0.2/1,000 live births, at maximum but still, with no effect on late-onset GBS. 
(77, 180, 181) IAP is given either as a result of positive maternal antenatal screening or due 
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to risk of high maternal colonisation, where each strategy has advantages and disadvantages, 
e.g. false-negative screening cultures, fast and unexpected labour where a timely correct IAP 
is not possible, and increased antibiotic therapy. (161) Furthermore, the most adapted IAP 
strategy is screening based IAP. With screening based IAP up to 35% of all women in labour 
will receive antibiotics which will affects the infants’ gut microbiome leading to a higher 
occurrence of intestinal bacteria with AMR. (182) LOS has not increased after the 
introduction of IAP, but the pattern has changed, and IAP is a possible risk factor for LOS 
with gram-negative bacteria expressing AMR. (181, 183, 184) Therefore, finding other 
prevention strategies is urgently required to decrease morbidity and mortality from invasive 
GBS disease, and vaccines are in development which could be delivered to pregnant women. 
(185)  
6.5.3 Candida prophylaxis to very-low birth weight  
Another example of targeted antimicrobial prophylaxis is fluconazole prophylaxis to very-
low birth weight premature children. After the introduction of candida prophylaxis in 2010, 
candidemia decreased significantly in our cohort. Only three episodes of candidemia were 
detected in the neonatal wards after the introduction of prophylaxis, in contrast to 50 
episodes, including four fatalities, before its introduction. The risk for invasive fungal 
infections is reported to be 2–4% of very-low birth weight infants and may affect 4–16% of 
extremely low birth weight infants with substantial morbidity and mortality. (186) 
6.5.4 Increase in BSI with Staphylococcus aureus 
With the decrease of the above-described pathogens, the proportion of the other isolated 
pathogens increased over time. Incidences of S. aureus isolation increased during the study 
period. It was the most frequently isolated bacteria in all age groups as well as in all risk 
groups, but with different clinical characteristics. BSI with S. aureus (SAB) increased in 
community-acquired infections in children with no underlying co-morbidity, and in children 
having signs of focal infection with arthritis, osteomyelitis, skin-or soft tissues infections or 
pulmonary involvement. Most SAB in children with HAI was without focal presentation, and 
was highly associated with the presence of an intravascular access, which has also been 
described among neonates. (187) Whether the high frequency of S. aureus reflects an actual 
systemic infection in all cases could be debatable. For instance, Denniston et al. suggested 
that up to 20% of all blood cultures positive for S. aureus were contaminants. (188) However, 
due to the retrospective design of my studies, it was impossible to distinguish between 
systemic infection and contamination in most cases. 
 
6.6 ANTIMICROBIAL RESISTANCE INCREASE 
During the study period, AMR increased, but the antimicrobial use did not increase. In paper 
III, we found a decrease in the prescription for 3rd generations cephalosporins. We did not 
find such a decrease in paper V. In paper III, neonates were omitted, and in paper V, only 
the most prescribed parenteral antibiotics were evaluated. This may hamper the comparison 
between the results. However, the increased AMR did not result in an increase in 
antimicrobial use at our hospital. We also know that antimicrobial out-patients prescriptions 




Somewhat surprisingly, we observed an increase in AMR among patients with no underlying 
comorbidity, with no previous antibiotic therapy, and with community-acquired infections, as 
well as in oncology patients, which is the paediatric group with the highest antimicrobial 
consumption (paper III and V). We also found a large proportion of children with a travel 
history to non-Nordic countries among children with isolates expressing AMR. 
Increase in AMR in different groups of patients also represents the differences in the 
mechanism of AMR, in terms of both transmission and prevention. 
Resistant species found in children with community-acquired infections reflects the 
occurrence of AMR in the community, which relates to the total consumption of 
antimicrobials in society (189) The import of antimicrobial-resistant bacteria through 
travellers returning from countries with higher rates of AMR is reported from several studies. 
(140, 141, 190). In oncology patients who are exposed to many episodes with antimicrobials, 
there is most likely a selection pressure on their microbiota, with increased risk of developing 
resistant bacteria subpopulations. (191-193). Nosocomial infections may increase the risk of 
AMR. Luckily, during the study period, there was only one outbreak of ESBL-producing K. 
pneumoniae in 2007. (194) The lack of spread of AMR in the NICU and PICU is in contrast 
to reports from other intensive care units (146, 195) could perhaps reflect a good hygiene 
standard.  
Based on our studies, we could not make any conclusion of the reasons for the increased 
AMR in our hospital. Nevertheless, we do know that AMR is a natural evolutionary response 
to antimicrobial exposure where antimicrobial molecules produced naturally by 
microorganism has existed for millions of years. (196) In an ecosystem (e.g., the human 
microbiota) free from external antimicrobial selection pressure, antimicrobial-resistant and 
non-resistant species co-exist in a stable balance. (197) Antibiotic therapy changes this 
balance, and antimicrobial drugs exert selection pressure on the microorganism in favour of 
species that are resistant to the antimicrobials used. Increased use of antimicrobials will, 
therefore, naturally increase the occurrence of AMR, and lowering their use will reduce AMR 
(198). In Sweden, administering growth-promoting antibiotics and prophylactic antibiotics to 
healthy animals is banned since 1986. Sales of antibiotics for animals are stable and at a low 
level, with mostly narrow-spectrum antibiotics, and contribute to only 12 % of the total 
antimicrobial consumption in Sweden. The occurrence of AMR in isolates from animal 
samples of Swedish origin is low. (110) This low use and occurrence of AMR contrast with 
other some European countries where antibiotics are used in healthy food-producing animals. 
Countries with high antibiotic use in healthy life stocks also have a high occurrence of AMR. 
(113) Our results indicate that the increase of AMR is related to travel history to non-nordic 
countries with implications on strategies to reduce the increased AMR. To avoid 
inappropriate antimicrobial use in hospital is essential, but efforts to inform policymakers 
about the importance of political decisions to reduce the global threat of antimcrobial 





6.7 IMPLEMENTATION OF PREVENTION STRATEGIES  
6.7.1 Antibiotic stewardship programme 
In paper III, we found around 40% of all admitted patients receiving antimicrobial therapy 
whereof 70% of all received parenteral antibiotics were third-generation cephalosporins, 
piperacillin-tazobactam and meropenem. Still, it was mostly evaluated as appropriate 
prescription and in accordance with guidelines. However, we also concluded that guidelines 
were missing in almost half of the prescription for both CAI, HAI and surgical prophylaxis. 
From the result, it was also not possible to evaluate if initiating or continuation of the 
antibiotic prescription was appropriate or not. Similar surveys of antimicrobial prescription in 
European paediatric hospital reveal a similarly high rate of prescription where authors 
advocated antimicrobial stewardship program and continuous surveillance of antimicrobial 
use. (199, 200) 
In the US, 84% of the hospitals reported to have a stewardship program, and the CDC reports 
a 5% decrease of antibiotic prescription in the outpatient settings and a 15% decline in 
paediatric prescriptions. (139) Although there is evidence in support the introduction of 
paediatric antimicrobial stewardship programmes in term of reduced antibiotic usage, 
improved prescriptions quality, and cost-savings, there is, at present, no consensus for the 
best strategy. Different interventions are required in different settings. (201) ASP targeting 
early consultation of an infectious specialist in S. aureus BSI had an effect, with an increased 
number of performed, prolonged intravenous antibiotic therapy as an indicator, improved 
management but did not affect outcomes. (131) The absence of effect on outcome may also 
reflect possible lower-risk catheter-related complications in children compared to adults (74) 
Reduction of antibiotic consumption, and limited use of broad-spectrum antibiotics has been 
reported in ASP program applied in neonatal settings (194). Finally, a significant impact on 
antimicrobial use and healthcare cost in pediatric stewardship programmes is reported in 
studies from the US. Surveillance data regarding antimicrobial use and antibiotic resistance is 
considered essential for planning and assessment of local stewardship programmes. (202) 
6.7.2 Hygiene measurements 
Our studies revealed high occurrence of S. aureus; 70% of SAB were HAI in children with 
underlying disease, cancer and children warded at the neonatal unit. Previous, 
implementation of national infections-control measurements showed a significantly decreased 
of catheter-associated bacteraemia where the decrease was most evident for CoNS but 
observed for all pathogens. (67) Similar significant reduction of CoNS is shown in neonatal 
settings after implementation of the infection control measurements, scrub the hub. (203). 
The use of a central line bundle protocol is well established, but adherence to the 
recommended time-bed measures could possible improve with education. (204) In addition to 
the type of intervention, the structure of the implementation is also of great importance. 
Designated, trained team leaders with skills to disseminate information to multi professionals 







In summary, this thesis adds knowledge about the aetiology and epidemiology of BSI in 
children from a Swedish perspective. The findings are of high importance for designing 
empiric antibiotic therapy regimes and for planning targeted measures to improve therapy and 
preventions of BSI.’ 
We concluded that epidemiology and aetiology for BSI were age-related and varied with 
underlying co-morbidity over the study period. Nowadays, BSI in children without 
underlying co-morbidity is a rare condition, caused by a limited number of pathogens, but 
often associated with signs of a focal infection. Not surprisingly, children with cancer and 
premature neonates were the groups with the highest risk for BSI. On the contrary to healthy 
children, aetiology of BSI in children with cancer and underlying co-morbidity was diverse, 
closely related to risk factors and partly age-related. Despite the fact that the proportion of 
children with BSI and underlying co-morbidity increased during the study period, there was a 
decreasing trend of paediatric BSI and mortality attributed to BSI. 
Over the study period, several strategies to reduce BSI was successfully implemented. The 
introduction of a vaccine against Streptococcus pneumoniae had most impact and decreased 
the incidence of BSI and the occurrence of meningitis in children. But also the 
implementation of a risk-based IAP program reduced the risk for GBS EOS. However, it was 
also evident that a risk-based IAP needs to be monitored carefully to ensure that it reaches all 
potential cases. Introduction of antifungal prophylaxis to selected neonates was also effective 
to prevent invasive candida infection. 
The occurrence of resistant bacteria, in particular E.coli ESBL, increased during the last years 
of the study period but could not be attributed to an increase in hospital antimicrobial 
consumption. The most prescribed drugs were third-generation cephalosporins and 
piperacillin-tazobactam. Therefore, we conclude that changes in antimicrobial therapy 


















 FUTURE PERSPECTIVE 
8.1  CONTINUOUS MONITORING OF BSA AND AMR  
• My studies show the importance of longitudinal monitoring of changes in aetiology. 
Continuous, structural, prospectively collection of aetiology and patients 
characteristics will continue to be of interest and importance. 
• The attempts to cover a large area have reduced the possibility of analyzing 
interesting findings in more detail. The results are inspiring and raise several 
questions for the future. 
8.2 PROPER USE OF ANTIBIOTICS 
• Our results provide a baseline for antibiotic prescribing in our hospital and could 
serve as a ground to start an antibiotic stewardship program. I also believe that 
repeated point prevalence surveys need to be part of the paediatric antibiotic 
stewardship strategy to identify prescribing trends over time, to evaluate the efficacy 
of ASPs and to tackle the issue of suboptimal antibiotic use. International 
standardised PPS with a further linkage between antibiotic prescribing and AMR will 
be critical to characterise appropriate use of antibiotics in hospitalised children and to 
propose guidance on the management of paediatric infections taking into account 
resistance profiles. 
 
• I hope that Sweden will establish a national network of paediatric hospitals to 
evaluate the antibiotic consumption for hospitalised children on a national level. The 
overall aim for such a network should be to identify areas for optimising antibiotic 
prescribing for hospitalized children. 
8.3 NEW INSIGHT- NEW THERAPEUTIC APPROACHES AND POSSIBILITIES 
• There is an enormous increase in knowledge on the immunological response to 
infections over the last two decades, both regarding individual differences but also 
regarding different response to different pathogens. The genetic contribution to the 
severity of infection may be substantial. This insight will probably lead to the 
possibility to identify individuals with increased risk for sepsis. Genome-wide studies 
are allowing research on the impact of genetics on the susceptibility to, and severity 
of infections. We need to include more of our patients in studies addressing these 
issues.  
8.4 INTERACTION BETWEEN CLINICS AND ACADEMY 
After over 20 years of clinical experience and ten years of efforts to combine clinical 
work with research, I am confident that it is possible to improve this collaboration 
further. Collaborative projects between clinicians and the academic society with mutual 






 SUMMARY OF THE THESIS IN SWEDISH 
Infektioner drabbar alla barn, är i allmänhet orsakade av virus och läker ofta ut inom loppet 
av dagar. Upp till 10% av alla infektioner är bakteriella och kan behöva antibiotika för att 
läka ut och inte utvecklas till en allvarlig infektion. Enligt beräkningar dör 3.2 miljoner 
barn varje år pga infektioner varav 44 % inträffar i nyföddhetsperioden. Över hälften 
bedöms vara möjliga att förebygga med bl.a. en fungerande sjukvård, vaccinationsprogram, 
tillgång till antibiotika och andra läkemedel. Majoriteten av all infektionsrelaterad dödlighet 
hos barn sker i länder med sämre tillgång till detta. Även i länder med god tillgång till 
sjukvård orsakar infektioner stort behov av sjukhusvård och dödsfall. Infektioner med växt 
av bakterier i blod, blodinfektioner, är en av de mer allvarliga infektionerna med en 
betydande risk för död.  
Avgörande för framgångsrik behandling av blodinfektioner är tidig upptäckt och att snabbt 
inleda behandling. Ett stor hot mot behandling av infektioner är den globala ökningen av 
antibiotikaresistens. Effektiv antibiotikabehandlingen kräver kunskap om vilka bakterier 
som med störst sannolikhet orsakar blodinfektion och i vilken utsträckning dessa bakterier 
är resistenta mot förstalinjens antibiotikabehandling. Det finns avgörande skillnader mellan 
olika länders förekomst av bakterier och resistensmönster Det föreligger bristande kunskap 
om bakterier och antibiotikaresistens vid blodinfektioner hos barn i Sverige.  
Vi har i detta avhandlingsarbete velat öka kunskapen om blodinfektioner hos barn genom 
att studera vilka typer av bakterier som drabbar vilka barn, underliggande risker för att 
drabbas och förekomsten av resistenta bakterier.  
Avhandlingen beskriver förekomsten av blodinfektioner under en 20-årsperiod. Vi har 
utgått från resultatet av 60,000 blododlingar erhållna från barn 0-17 år som har vårdats på 
Astrid Lindgrens Barnsjukhus, Karolinska Universitetssjukhuset i Stockholm 1998-2018. 
Vi har även studerat hur antibiotikaförskrivningen har sett ut under perioden. Resultaten 
från forskningen har presenterats i fem delarbeten varav fyra har publicerats som artiklar i 
vetenskapliga tidskrifters och det femte delarbetet föreligger i manus.  
I delarbete I analyserade vi resultatet av 1,097 blododlingar tagna på barn 0-17 år med 
misstanke om infektion under perioden 1998-2008. I genomsnitt insjuknande ett av 2500 
barn med blodinfektion orsakad av någon typ av bakterie. Risken var dock avsevärt högre 
för nyfödda barn där risken var ett av 434 nyfödda barn medan endast ett av 5000 barn i 
åldersgruppen 6-17 år drabbades. Barn med cancer var den patientgrupp som hade störst 
risk för blodinfektion. Risken att dö vid blodinfektion var 14.4% bland nyfödda, 5.4% hos 
barn med underliggande sjukdomar och 1.7% hos tidigare friska barn. Stafylokocker var 
den vanligaste bakterien. Hos tidigare friska barn utgjorde några få bakterier närmast alla 
positiva blododlingar. Barn med underliggande sjukdomar riskerade att bli infekterade av 
många fler olika sorters bakterier vilket har betydelse för vilken antibiotika som skall 
väljas.  
I delarbete II utvärderade vi effekten av två olika infektionsförebyggande åtgärder. 2007 
introducerade vaccination för att skydda mot pneumokocker och 2008 infördes ett 
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åtgärdsprogram med att ge antibiotika till födande kvinnor med ökad risk för att överföra 
Grupp B streptokocker (GBS) till sina barn. Vi jämförde förekomsten av pneumokocker 
och GBS under två femårsperioder, före och efter att åtgärderna införts. Båda åtgärder var 
effektiva. För pneumokocker minskade risken med 62% bland de barn som haft störst risk 
för pneumokockinfektion, 3 månader- 3 års ålder. Bland nyfödda barn <7dgr minskade 
risken att få en allvarlig GBS infektion med 60%. För både pneumokocker och GBS 
minskade även hjärnhinneinflammationer med 70%.  
I delarbete III genomförde vi åtta endagarsmätningar över antibiotikaförskrivningen för 
alla patienter som vårdades på sjukhuset den specifika dagen. Trots få mätpunkter anses 
den typen av undersökning ge en representativ bild. Vi fann en förändring av 
antibiotikaförskrivningen över tid. Förebyggande behandling till utvalda patientgrupper 
ökade. Andelen av de sjukhusvårdade som fick antibiotika mot samhällsförvärvade 
infektioner minskade. Av alla som vårdades fick i genomsnitt 36% antibiotika vilket 
ändrades? tydligt under perioden. Sepsis, oklar feber hos barn med cancerbehandling, 
bukinfektioner och lunginflammation var de vanligaste anledningarna till behandling.  
Delarbete IV var en uppföljning av delarbete I och II för att undersöka om förändringarna 
bestod och upptäcka eventuellt nya förändringar. Sammanlagt analyserades 2,079 positiva 
blododlingar under perioden 1998-2018. Risken att insjukna med blodinfektion minskade. 
Effekten av de infektionsförebyggande åtgärderna beskrivna i arbete II kvarstod och var 
huvudorsaken till minskningen tillsammans med svampförebyggande behandling till 
mycket förtidigt födda barn med mycket låg födelsevikt. Förändringarna bidrog till en 
minskad dödlighet bland nyfödda barn. Samtidigt kunde vi notera en ökning av tidiga GBS 
infektioner slutet av studietiden men orsakerna har ännu inte studerats.  
I delarbete V granskade vi förekomsten av resistenta bakterier bland alla barn som haft 
blodinfektioner under hela perioden. 9.2% av de 2,079 blodinfektionerna hade någon typ av 
resistens. Förekomsten av resistenta bakterier ökade. Bland barn utan underliggande 
sjukdomar ökade antalet stafylokocker resistenta mot clindamycin och antalet 
pneumokocker resistenta mot antibiotika-macrolider, tetracyklin och trimetoprim-sulfa. För 
barn med underliggande sjukdomar noterades 15% av E. coli producera ESBL under de 
sista 5 åren, då MRSA noterades bland 3 % av alla Stafylokock infektioner. Utlandsvistelse 
bedömdes som en riskfaktor för både ESBL och MRSA. Antibiotikaförbrukningen ökade 
inte under perioden och bedöms ej kunna förklara ökningen av resistens.  
Sammanfattningsvis konstaterar vi att blodinfektioner bland barn utan underliggande 
sjukdomar är ovanligt och att vaccination mot de vanligaste och farligaste bakterierna är ett 
effektivt sätt att minska sjukdom. Förtidigt nyfödda barn med underliggande sjukdomar och 
barn som behandlas mot cancer har en betydligt större risk för blodinfektioner. De drabbas 
också delvis av andra bakterier där risken för resistenta bakterier ökar oroande. Åtgärder för 
att minska risken för infektioner hos dessa grupper behöver sannolikt rikta sig specifikt till 
respektive riskgrupp. En viktig förebyggande åtgärd är att försöka minska infektioner 






Först och främst vill jag tacka mina handledare för all hjälp och stöd med struktur och 
framåtdrift. 
Margareta Eriksson, min kära och mycket unika arbetskamrat. Min ursprungliga 
huvudhandledare. Myten och legenden, anledningen till att jag ville till Astrid Lindgren från 
Sachsska, till all din kunskap och erfarenhet, det har jag aldrig ångrat. Du har lärt mig så 
mycket om barninfektion. Din arbetsinsats är en mycket stor del av denna avhandling 
Anna Nilsson, min huvudhandledare och livboj. Utan dig hade jag inte kommit i mål. Du 
strukturerar, uppmuntrar, redigerar och lotsar med briljans, värme och inkännande. 
Christian Giske, min bihandledare vars enorma kompetens inom mikrobiologi och 
antibiotikaresistens jag bara har fått snudda vid men din roll och ditt stöd har likväl varit 
avgörande med värdefulla och viktiga bidrag till alla arbeten.  
 
Dessutom ett tack till följande personer som på olika sätt har bidragit till detta 
avhandlingsarbete, min professionella och personliga utveckling 
  
Rutger Bennet, starkt bidragande medförfattare till alla arbeten. Min rumskamrat, kollega, 
och gåtfulla person som sällan blir förvånad men som själv ofta överraskar med kunskap och 
tusen olika förmågor. 
Kerstin Hermansson, vår ständiga sekreterare som har gjort en ovärderlig insats för att samla 
in data. 
Per Nydert, för värdefullt bidrag till sista arbetet. Jag hoppas att vi kan samarbeta mer med 
varandra.  
All you authors to my references out there around the globe. I have shared more time with 
you tan my family for the last couples of months. I thank you for all your work  
Ida Hed Myrberg, för hjälp med statistiska bearbetningar, du borde förstås ha varit med mer 
och tidigare. 
Christophe Pedroletti, för att du med all din fantastiska energi startade barninfektionsenheten 
på Astrid Lindgren, lät mig bli en i gruppen och var en så inspirerande chef.  
Klas Ekström, du gav mig förtroendet att bli chef över barninfektion i en stor och besvärlig 
förändringsprocess. Ett uppdrag som gav mig insikten att jag föredrar klinik och kraften att 
slutföra det här projektet.  
Lisbeth Rosengren, Åsa Laestadius, Maria Berner & Malin Ryd Rinder, för att ni som chefer 
i olika faser av min långa doktorandperiod har underlättat och hjälpt mig att få tid för 
forskning och att gå doktorandkurser.  
Olof Hertting, I lust och nöd, nu känns det som att det är dags för lust. Vi har kämpat några år 
för en infektionsenhet, jag är så glad att du hållit ut att du har dragit att stort lass några år. 
Längtar efter att äntligen få arbeta närmare med dig, käre kollega och vän. 
Amelie Sandart, Siggi Arnason, Selma Olsson Åkefelt, Charlotte Buxbaum, Aida Wahlgren, 
mina kollegor som i stor utsträckning bidrar till en meningsfull arbetstillvaro. Dessutom har 
ni genom ert arbete givit mig möjlighet att forska, en avgörande förutsättning för att ha 
möjlighet att forska.  
Maria Nilsson, Lena Ljungbäck för många år på Q80 och nu för väldigt lätt och roligt 




Gunnar Lilja, min lugna trygga faderliga första chef på Sachsska. Som gav mig känsla av att 
kunna och våga. 
Birger Winbladh, min pedagogiska förebild 1. Ditt sätt att nyfiket, engagerat, ödmjukt, 
uppmuntrande, vänligt, strukturerat och superprofessionellt ta emot studenter och nya 
kollegor skapade en helt unik atmosfär för lärande och utveckling.  
Anders Dahlström, min pedagogiska förebild 1:2. För de mest fantastiska 
teamkommunikations- & återkopplings-träningar som finns. Mr. CEPS det är så det ska gå 
till.  
Kalle Lidefeldt, Ingela Bollgren, Lasse Browaldh, Hanna Kapadia, Wille Masreliez, Bodil 
Schiller, Anders Åhlin och flera andra erfarna kollegor under min tid på Sachsska, jag anade 
då men insåg inte riktigt hur viktiga ni var för en professionell utveckling. 
Felicia Nordenstam, förutom nästan livslång vänskap vill jag tacka dig för att du lockade mig 
till att bli barnläkare, -vilket jobb, det ger mig glädje varje dag. 
La Familia, Percy, Christian, Debbie, Kristina, Maria, Per W, Karin, Per B, Anna och 
Samuel. Tack kära gäng för att ni bidrar med gemenskap, glädje, inspiration och visioner. 
Alla andra goda arbetskamrater på Astrid Lindgrens barnsjukhus som finns runt omkring 
och tillsammans skapar en fantastisk arbetsplats att längta till, hantera och glömma bort 
bekymmer, sorger och besvär.  
 
 
Charlotte Alva Kristina Millde Luthander, hela du min älskade. Mitt norr, mitt söder, mitt 
väst och öst. Du ger riktning och stadga i min tillvaro, vila glädje och kärlek. Vilken tur jag 
hade.   
Alice och Felix mina älskade barn som så fint tonar in, frågar och ser. För att ni finns, för att 
ni är och fyller mig med glädje och mening 
Inger Luthander, min mamma och min tvillingsyster Maria Luthander, mitt ursprung, mina 
referenspunkter och så otroligt betydelsefulla i mitt liv. 
Min övriga fina, kära och närvarande familj. svärmor Kina, bror Sebastian och syster Julia 
med familjer, Ann-charlotte, nevöer Rasum och Fabian med respektive, svåger Fredirik med 
Anette, Nellie, Emil och Julia, styvfar Lasse med familj för det liv vi delar. 
Pappa Leif och Svärfar Reje för att ni fanns och fortfarande är viktiga i mitt liv 
 
Och slutligen tack till;  
följande bidragsgivare; Stiftelsen samariten, Jerring fonden, Sällskapet Barnavård 
Institutionen för Kvinnors och barns hälsa Karolinska Institutet, ALF-medel och FoUUi-












1. Vos T, Barber RM, Bell B, Bertozzi-Villa A, Biryukov S, Bolliger I, et al. 
Global, regional, and national incidence, prevalence, and years lived with disability for 301 
acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for 
the Global Burden of Disease Study 2013. The Lancet. 2015;386(9995):743-800. 
2. Wang H, Liddell CA, Coates MM, Mooney MD, Levitz CE, Schumacher AE, 
et al. Global, regional, and national levels of neonatal, infant, and under-5 mortality during 
1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet. 
2014;384(9947):957-79. 
3. Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, et al. Global, 
regional, and national causes of child mortality: an updated systematic analysis for 2010 with 
time trends since 2000. The Lancet. 2012;379(9832):2151-61. 
4. UNICEF W, World Bank Group and United Nations. United Nations Inter-
agency Group for Child Mortality Estimation (UN IGME), ‘Levels & Trends in Child 
Mortality: Report 2019, Estimates developed by the United Nations Inter-agency Group for 
Child Mortality Estimation’, United Nations Children’s Fund,New York, 2019. 2019. 
5. Fleischmann-Struzek C, Goldfarb DM, Schlattmann P, Schlapbach LJ, Reinhart 
K, Kissoon N. The global burden of paediatric and neonatal sepsis: a systematic review. 
Lancet Respir Med. 2018;6(3):223-30. 
6. Hasegawa K, Tsugawa Y, Cohen A, Camargo CA. Infectious Disease-related 
Emergency Department Visits Among Children in the US. The Pediatric Infectious Disease 
Journal. 2015;34(7):681-5. 
7. Weiss SL, Fitzgerald JC, Pappachan J, Wheeler D, Jaramillo-Bustamante JC, 
Salloo A, et al. Global epidemiology of pediatric severe sepsis: the sepsis prevalence, 
outcomes, and therapies study. Am J Respir Crit Care Med. 2015;191(10):1147-57. 
8. Hartman ME, Saeed MJ, Powell KN, Olsen MA. The Comparative 
Epidemiology of Pediatric Severe Sepsis. Journal of Intensive Care Medicine. 
2019;34(6):472-9. 
9. Ruth A, Mccracken CE, Fortenberry JD, Hall M, Simon HK, Hebbar KB. 
Pediatric Severe Sepsis. Pediatric Critical Care Medicine. 2014;15(9):828-38. 
10. Ladhani S, Pebody RG, Ramsay ME, Lamagni TL, Johnson AP, Sharland M. 
Continuing Impact of Infectious Diseases on Childhood Deaths in England and Wales, 2003–
2005. The Pediatric Infectious Disease Journal. 2010:1. 
11. Weiss SL, Peters MJ, Alhazzani W, Agus MSD, Flori HR, Inwald DP, et al. 
Surviving sepsis campaign international guidelines for the management of septic shock and 
sepsis-associated organ dysfunction in children. Intensive Care Medicine. 2020;46(S1):10-67. 
12. Emr BM, Alcamo AM, Carcillo JA, Aneja RK, Mollen KP. Pediatric Sepsis 
Update: How Are Children Different? Surgical Infections. 2018;19(2):176-83. 
13. Aneja RK, Carcillo JA. Differences between adult and pediatric septic shock. 
Minerva Anestesiol. 2011;77(10):986-92. 
14. Randolph AG, Mcculloh RJ. Pediatric sepsis. Virulence. 2014;5(1):179-89. 
15. Ygberg S, Nilsson A. The developing immune system - from foetus to toddler. 
Acta Paediatrica. 2012;101(2):120-7. 
16. S. Wheeler D. ”Children are not Small Adults!“. The Open Inflammation 
Journal. 2011;4(1):4-15. 
17. Agyeman PKA, Schlapbach LJ, Giannoni E, Stocker M, Posfay-Barbe KM, 
Heininger U, et al. Epidemiology of blood culture-proven bacterial sepsis in children in 




18. Bielicki JA, Lundin R, Sharland M. Antibiotic Resistance Prevalence in 
Routine Bloodstream Isolates from Children’s Hospitals Varies Substantially from Adult 
Surveillance Data in Europe. The Pediatric Infectious Disease Journal. 2015;34(7):734-41. 
19. Greenhow TL, Hung Y-Y, Herz AM. Changing Epidemiology of Bacteremia in 
Infants Aged 1 Week to 3 Months. PEDIATRICS. 2012;129(3):e590-e6. 
20. Van Den Bruel A, Bartholomeeusen S, Aertgeerts B, Truyers C, Buntinx F. 
Serious infections in children: an incidence study in family practice. BMC Family Practice. 
2006;7(1). 
21. Verbakel JY, Lemiengre MB, De Burghgraeve T, De Sutter A, Aertgeerts B, 
Bullens DMA, et al. Validating a decision tree for serious infection: diagnostic accuracy in 
acutely ill children in ambulatory care. BMJ Open. 2015;5(8):e008657. 
22. Leroy S, Bressan S, Lacroix L, Andreola B, Zamora S, Bailey B, et al. Refined 
Lab-score, a Risk Score Predicting Serious Bacterial Infection in Febrile Children Less Than 
3 Years of Age. The Pediatric Infectious Disease Journal. 2018;37(5):387-93. 
23. Martinón-Torres F, Salas A, Rivero-Calle I, Cebey-López M, Pardo-Seco J, 
Herberg JA, et al. Life-threatening infections in children in Europe (the EUCLIDS Project): a 
prospective cohort study. Lancet Child Adolesc Health. 2018;2(6):404-14. 
24. Tambe P, Sammons HM, Choonara I. Why do young children die in the UK? A 
comparison with Sweden. Archives of Disease in Childhood. 2015;100(10):928-31. 
25. Tambe P, Sammons HM, Choonara I. Child mortality of children aged 5–15 
years in the UK and Sweden: a comparison. Archives of Disease in Childhood. 
2016;101(4):409-10. 
26. The National Board of Health and Welfare. 
https://sdb.socialstyrelsen.se/if_par/val.aspx. Accessed September 2020.  
27. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer 
M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-
3). JAMA. 2016;315(8):801. 
28. Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus 
conference: Definitions for sepsis and organ dysfunction in pediatrics*. Pediatric Critical 
Care Medicine. 2005;6(1):2-8. 
29. Schlapbach LJ, Straney L, Bellomo R, Maclaren G, Pilcher D. Prognostic 
accuracy of age-adapted SOFA, SIRS, PELOD-2, and qSOFA for in-hospital mortality 
among children with suspected infection admitted to the intensive care unit. Intensive Care 
Medicine. 2018;44(2):179-88. 
30. Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A, et 
al. Assessment of Clinical Criteria for Sepsis. JAMA. 2016;315(8):762. 
31. Matics TJ, Sanchez-Pinto LN. Adaptation and Validation of a Pediatric 
Sequential Organ Failure Assessment Score and Evaluation of the Sepsis-3 Definitions in 
Critically Ill Children. JAMA Pediatrics. 2017;171(10):e172352. 
32. Van Nassau SC, Van Beek RH, Driessen GJ, Hazelzet JA, Van Wering HM, 
Boeddha NP. Translating Sepsis-3 Criteria in Children: Prognostic Accuracy of Age-
Adjusted Quick SOFA Score in Children Visiting the Emergency Department With 
Suspected Bacterial Infection. Frontiers in Pediatrics. 2018;6. 
33. Chapman SM, Wray J, Oulton K, Pagel C, Ray S, Peters MJ. ‘The Score 
Matters’: wide variations in predictive performance of 18 paediatric track and trigger 
systems. Archives of Disease in Childhood. 2017;102(6):487-95. 
34. Balamuth F, Weiss SL, Neuman MI, Scott H, Brady PW, Paul R, et al. 
Pediatric Severe Sepsis in U.S. Children’s Hospitals*. Pediatric Critical Care Medicine. 
2014;15(9):798-805. 
35. Hartman ME, Linde-Zwirble WT, Angus DC, Watson RS. Trends in the 
epidemiology of pediatric severe sepsis*. Pediatr Crit Care Med. 2013;14(7):686-93. 
 
 71 
36. Mellhammar L, Wullt S, Lindberg Å, Lanbeck P, Christensson B, Linder A. 
Sepsis Incidence: A Population-Based Study. Open Forum Infectious Diseases. 
2016;3(4):ofw207. 
37. Schuller KA, Hsu BS, Thompson AB. The Rate of Sepsis in a National 
Pediatric Population, 2006 to 2012. Clinical Pediatrics. 2017;56(11):1001-7. 
38. Schlapbach LJ, Straney L, Alexander J, Maclaren G, Festa M, Schibler A, et al. 
Mortality related to invasive infections, sepsis, and septic shock in critically ill children in 
Australia and New Zealand, 2002–13: a multicentre retrospective cohort study. The Lancet 
Infectious Diseases. 2015;15(1):46-54. 
39. Herz AM, Greenhow TL, Alcantara J, Hansen J, Baxter RP, Black SB, et al. 
Changing Epidemiology of Outpatient Bacteremia in 3- to 36-Month-Old Children After the 
Introduction of the Heptavalent-Conjugated Pneumococcal Vaccine. The Pediatric Infectious 
Disease Journal. 2006;25(4):293-300. 
40. Henderson KL, Johnson AP, Muller-Pebody B, Charlett A, Gilbert R, Sharland 
M. The changing aetiology of paediatric bacteraemia in England and Wales, 1998–2007. 
Journal of Medical Microbiology. 2010;59(2):213-9. 
41. Larru, Beatriz, MD, PhD, Gong, Wu, et al. Bloodstream Infections in 
Hospitalized Children: Epidemiology and Antimicrobial Susceptibilities. Pediatr Infect Dis 
J. 2016;35(5):507-510. doi:10.1097/INF.0000000000001057.  
42. Doern C. The Art and Science of the Pediatric Blood Culture. Clinical 
Microbiology Newsletter. 2020;42(16):134-6. 
43. Lamy B, Dargère S, Arendrup MC, Parienti J-J, Tattevin P. How to Optimize 
the Use of Blood Cultures for the Diagnosis of Bloodstream Infections? A State-of-the Art. 
Frontiers in Microbiology. 2016;7. 
44. Kellogg JA, Manzella JP, Bankert DA. Frequency of Low-Level Bacteremia in 
Children from Birth to Fifteen Years of Age. Journal of Clinical Microbiology. 
2000;38(6):2181-5. 
45. Isaacman DJ, Karasic RB, Reynolds EA, Kost SI. Effect of number of blood 
cultures and volume of blood on detection of bacteremia in children. The Journal of 
Pediatrics. 1996;128(2):190-5. 
46. Gonsalves WI, Cornish N, Moore M, Chen A, Varman M. Effects of Volume 
and Site of Blood Draw on Blood Culture Results. Journal of Clinical Microbiology. 
2009;47(11):3482-5. 
47. Connell TG, Rele M, Cowley D, Buttery JP, Curtis N. How Reliable Is a 
Negative Blood Culture Result? Volume of Blood Submitted for Culture in Routine Practice 
in a Children's Hospital. PEDIATRICS. 2007;119(5):891-6. 
48. Youssef AS, Fanous M, Siddiqui FJ, Estrada J, Chorny V, Braiman M, et al. 
Value of Blood Cultures in the Management of Children Hospitalized with Community-
Acquired Pneumonia. Cureus. 2020. 
49. Myers AL, Hall M, Williams DJ, Auger K, Tieder JS, Statile A, et al. 
Prevalence of Bacteremia in Hospitalized Pediatric Patients With Community-acquired 
Pneumonia. The Pediatric Infectious Disease Journal. 2013;32(7):736-40. 
50. Urinary Tract Infection: Clinical Practice Guideline for the Diagnosis and 
Management of the Initial UTI in Febrile Infants and Children 2 to 24 Months. 
PEDIATRICS. 2011;128(3):595-610. 
51. Megged O. Bacteremic vs nonbacteremic urinary tract infection in children. 
The American Journal of Emergency Medicine. 2017;35(1):36-8. 
52. Strålin K, Rothman RE, Özenci V, Barkataki K, Brealey D, Dhiman N, et al. 
Performance of PCR/Electrospray Ionization-Mass Spectrometry on Whole Blood for 
Detection of Bloodstream Microorganisms in Patients with Suspected Sepsis. Journal of 
Clinical Microbiology. 2020;58(9). 
 
72 
53. Desmet S, Maertens J, Bueselinck K, Lagrou K. Broad-Range PCR Coupled 
with Electrospray Ionization Time of Flight Mass Spectrometry for Detection of Bacteremia 
and Fungemia in Patients with Neutropenic Fever. Journal of Clinical Microbiology. 
2016;54(10):2513-20. 
54. Spaulding AB, Watson D, Dreyfus J, Heaton P, Grapentine S, Bendel-Stenzel 
E, et al. Epidemiology of Bloodstream Infections in Hospitalized Children in the United 
States, 2009–2016. Clinical Infectious Diseases. 2019;69(6):995-1002. 
55. Greenhow TL, Hung Y-Y, Herz A. Bacteremia in Children 3 to 36 Months Old 
After Introduction of Conjugated Pneumococcal Vaccines. Pediatrics. 
2017;139(4):e20162098. 
56. Laupland KB GD, Vanderkooi OG, Ross T, Kellner JD. The changing burden 
of pediatric bloodstream infections in Calgary, Canada, 2000-2006. Pediatr Infect Dis J. 
2009;28(2):7. 
57. Boeddha NP, Schlapbach LJ, Driessen GJ, Herberg JA, Rivero-Calle I, Cebey-
López M, et al. Mortality and morbidity in community-acquired sepsis in European pediatric 
intensive care units: a prospective cohort study from the European Childhood Life-
threatening Infectious Disease Study (EUCLIDS). Crit Care. 2018;22(1):143. 
58. Ruiz-Azcona L, Santibañez M, Gimeno A, Roig FJ, Vanaclocha H, Ventero 
MP, et al. Etiology of bloodstream infections at a population level during 2013-2017 in the 
Autonomous Community of Valencia, Spain. Revista Española de Quimioterapia. 
2020;33(3):200-6. 
59. Skogberg K, Lyytikäinen O, Ollgren J, Nuorti JP, Ruutu P. Population-based 
burden of bloodstream infections in Finland. Clinical Microbiology and Infection. 
2012;18(6):E170-E6. 
60. Henderson A, Harris P, Hartel G, Paterson D, Turnidge J, Davis JS, et al. 
Benzylpenicillin versus flucloxacillin for penicillin-susceptible Staphylococcus aureus 
bloodstream infections from a large retrospective cohort study. International Journal of 
Antimicrobial Agents. 2019;54(4):491-5. 
61. Martin NG, Sadarangani M, Pollard AJ, Goldacre MJ. Hospital admission rates 
for meningitis and septicaemia caused by Haemophilus influenzae, Neisseria meningitidis, 
and Streptococcus pneumoniae in children in England over five decades: a population-based 
observational study. The Lancet Infectious Diseases. 2014;14(5):397-405. 
62. Hartman ME, Linde-Zwirble WT, Angus DC, Watson RS. Trends in the 
Epidemiology of Pediatric Severe Sepsis*. Pediatric Critical Care Medicine. 2013;14(7):686-
93. 
63. Farrell D, Nadel S. What’s New in Paediatric Sepsis. Current Pediatrics 
Reports. 2016;4(1):1-5. 
64. Laupland KB, Lyytikäinen O, Sgaard M, Kennedy KJ, Knudsen JD, Ostergaard 
C, et al. The changing epidemiology of Staphylococcus aureus bloodstream infection: a 
multinational population-based surveillance study. Clinical Microbiology and Infection. 
2013;19(5):465-71. 
65. Doit C M-KP, Mahjoub-Messani F, Bidet P, Bonacorsi S, Carol Am Varon E, 
Bingen E. Epidemiology of pediatric community-acquired bloodstream infections in a 
children hospital in paris, France, 2001-2008. Microbiology and Infections Disease. 
2010;66:4. 
66. Watt K, Waddle E, Jhaveri R. Changing Epidemiology of Serious Bacterial 
Infections in Febrile Infants without Localizing Signs. PLoS ONE. 2010;5(8):e12448. 
67. Pérerz Lopéz A, Ladhani SN, Breathnach A, Planche T, Heath PT, Sharland M. 




68. Woll C, Neuman MI, Pruitt CM, Wang ME, Shapiro ED, Shah SS, et al. 
Epidemiology and Etiology of Invasive Bacterial Infection in Infants ≤60 Days Old Treated 
in Emergency Departments. The Journal of Pediatrics. 2018;200:210-7.e1. 
69. Bressan S, Berlese P, Mion T, Masiero S, Cavallaro A, Da Dalt L. Bacteremia 
in feverish children presenting to the emergency department: a retrospective study and 
literature review. Acta Paediatrica. 2012;101(3):271-7. 
70. Török E ME, Cooke F. Oxfor handbook of Infectious diseases and 
microbiology: Oxford University press; 2010. 
71. Bennet R Eriksson M. Infektioner hos barn, Studentlitteratur 2013 upplga 1:1. 
72. Carrillo-Marquez MA HK, Mason EO, Kaplan SL. Clinical and molecular 
epidemiology of Staphylococcus aureus catheter-related bacteremia in children. Pediatr Infect 
Dis J. 2010 May;29(5):410-4. doi: 10.1097/INF.0b013e3181c767b6. PMID: 20431380. 
Pediatr Infect Dis J. 2010;29(5):5. 
73. Corkum KS, Jones, R. E., Reuter, C. H., Kociolek, L. K., Morgan, E., & Lautz, 
T. B. Central venous catheter salvage in children with Staphylococcus aureus central line-
associated bloodstream infection.  Pediatric surgery international ,  33 (11), 1201–1207. 
https://doi.org/10.1007/s00383-017-4165-5. Pediatric surgery international. 2017;33(11):6. 
74. Alby-Laurent F, Lambe C, Ferroni A, Salvi N, Lebeaux D, Le Gouëz M, et al. 
Salvage Strategy for Long-Term Central Venous Catheter-Associated Staphylococcus aureus 
Infections in Children. Frontiers in Pediatrics. 2019;6. 
75. Asner SA, Agyeman PKA, Gradoux E, Posfay-Barbe KM, Heininger U, 
Giannoni E, et al. Burden of Streptococcus pneumoniae Sepsis in Children After Introduction 
of Pneumococcal Conjugate Vaccines: A Prospective Population-based Cohort Study. 
Clinical Infectious Diseases. 2019;69(9):1574-80. 
76. Russell NJ, Seale AC, O'Sullivan C, Le Doare K, Heath PT, Lawn JE, et al. 
Risk of Early-Onset Neonatal Group B Streptococcal Disease With Maternal Colonization 
Worldwide: Systematic Review and Meta-analyses. Clin Infect Dis. 2017;65(suppl_2):S152-
S9. 
77. Bianchi-Jassir F, Seale AC, Kohli-Lynch M, Lawn JE, Baker CJ, Bartlett L, et 
al. Preterm Birth Associated With Group B Streptococcus Maternal Colonization Worldwide: 
Systematic Review and Meta-analyses. Clinical Infectious Diseases. 2017;65(suppl_2):S133-
S42. 
78. Edmond KM, Kortsalioudaki C, Scott S, Schrag SJ, Zaidi AKM, Cousens S, et 
al. Group B streptococcal disease in infants aged younger than 3 months: systematic review 
and meta-analysis. The Lancet. 2012;379(9815):547-56. 
79. Le Doare K, Kampmann B. Breast milk and Group B streptococcal infection: 
Vector of transmission or vehicle for protection? Vaccine. 2014;32(26):3128-32. 
80. Zimmermann P, Gwee A, Curtis N. The controversial role of breast milk in 
GBS late-onset disease. Journal of Infection. 2017;74:S34-S40. 
81. Puopolo KM, Lynfield R, Cummings JJ. Management of Infants at Risk for 
Group B Streptococcal Disease. Pediatrics. 2019;144(2):e20191881. 
82. Peltola H, Aavitsland P, Hansen G, Kjeld, Jónsdóttir E, Kristín, Nøkleby H, 
Romanus V. Perspective: A Five‐Country Analysis of the Impact of Four 
DifferentHaemophilus influenzaeType b Conjugates and Vaccination Strategies in 
Scandinavia. The Journal of Infectious Diseases. 1999;179(1):223-9. 
83. Peltola H. Worldwide Haemophilus influenzae Type b Disease at the Beginning 
of the 21st Century: Global Analysis of the Disease Burden 25 Years after the Use of the 
Polysaccharide Vaccine and a Decade after the Advent of Conjugates. 2000;13(2):302-17. 
84. Reddy EA, Shaw AV, Crump JA. Community-acquired bloodstream infections 




85. Public Health Agency of Sweden. 
http://www.folkhalsomyndigheten.se/folkhalsorapportering-statistik/statistik-a-
o/sjukdomsstatistik/meningokockinfektion-invasiv/ Accessed October2020  
86. Eriksson L, Hedberg ST, Jacobsson S, Fredlund H, Mölling P, Stenmark B. 
Whole-Genome Sequencing of Emerging Invasive Neisseria meningitidis Serogroup W in 
Sweden. Journal of Clinical Microbiology. 2018;56(4):JCM.01409-17. 
87. World Health Organization . https://www.who.int/en/news-room/fact-
sheets/detail/meningococcal-meningitis. Accessed October 2020  
88. Laupland KB. Incidence of bloodstream infection: a review of population-based 
studies. Clinical Microbiology and Infection. 2013;19(6):492-500. 
89. Persson E, Trollfors B, Brandberg LL, Tessin I. Septicaemia and meningitis in 
neonates and during early infancy in the Göteborg area of Sweden. Acta Paediatrica. 
2007;91(10):1087-92. 
90. Berardi A, Sforza F, Baroni L, Spada C, Ambretti S, Biasucci G, et al. 
Epidemiology and complications of late-onset sepsis: an Italian area-based study. PLOS 
ONE. 2019;14(11):e0225407. 
91. Didier C SM, Chognot D, Campagni R, Schnebelen A, Messer J, Donato L, 
Langer B, Meyer N, Astruc D, Kuhn P. Late-onset neonatal infections: incidences and 
pathogens in the era of antenatal antibiotics. Eur J Pediatr. 2012;4(171):6. 
92. Giannoni E, Agyeman PKA, Stocker M, Posfay-Barbe KM, Heininger U, 
Spycher BD, et al. Neonatal Sepsis of Early Onset, and Hospital-Acquired and Community-
Acquired Late Onset: A Prospective Population-Based Cohort Study. The Journal of 
Pediatrics. 2018;201:106-14.e4. 
93. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for 
nosocomial infections, 1988. American Journal of Infection Control. 1988;16(3):128-40. 
94. Haley RW, Meade Morgan W, Culver DH, White JW, Grace Emori T, Mosser 
J, et al. Update from the SENIC project. American Journal of Infection Control. 
1985;13(3):97-108. 
95. Gardner P, Carles DG. Infections acquired in a pediatric hospital. The Journal 
of Pediatrics. 1972;81(6):1205-10. 
96. Henderson KL, Müller-Pebody B, Johnson AP, Wade A, Sharland M, Gilbert 
R. Community-acquired, healthcare-associated and hospital-acquired bloodstream infection 
definitions in children: a systematic review demonstrating inconsistent criteria. Journal of 
Hospital Infection. 2013;85(2):94-105. 
97. Organization WH. Antimicrobial resistance:Global report on surveillance. 
ISBN 978 92 4 156474. 2014. 
98. O'Neill. Review on Antimicrobial Resistance. Antimicrobial Resistance: 
Tackling a Crisis for the Health and Wealth of Nations. 2014. 2014. 
99. De Kraker MEA, Stewardson AJ, Harbarth S. Will 10 Million People Die a 
Year due to Antimicrobial Resistance by 2050? PLOS Medicine. 2016;13(11):e1002184. 
100. Naylor NR, Atun R, Zhu N, Kulasabanathan K, Silva S, Chatterjee A, et al. 
Estimating the burden of antimicrobial resistance: a systematic literature review. 
Antimicrobial Resistance & Infection Control. 2018;7(1). 
101. World Health Organization. Global antimicrobial resistance surveillance system 
(GLASS) report: early implementation 2017-2018. Geneva: World Health Organization; 
2018. Licence: CC BY-- NC SA 3.0 IGO. 2018. 
102. Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, 
et al. Attributable deaths and disability-adjusted life-years caused by infections with 
antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a 
population-level modelling analysis. The Lancet Infectious Diseases. 2019;19(1):56-66. 
 
 75 
103. European Centre for Disease Prevention and Control. 
https://antibiotic.ecdc.europa.eu/en/about  Accessed October 2020  
104. Thompson PL, Spyridis N, Sharland M, Gilbert RE, Saxena S, Long PF, et al. 
Changes in clinical indications for community antibiotic prescribing for children in the UK 
from 1996 to 2006: will the new NICE prescribing guidance on upper respiratory tract 
infections just be ignored? Archives of Disease in Childhood. 2009;94(5):337-40. 
105. Fernández Urrusuno R, Flores Dorado M, Vilches Arenas A, Serrano Martino 
C, Corral Baena S, Montero Balosa MC. Improving the appropriateness of antimicrobial use 
in primary care after implementation of a local antimicrobial guide in both levels of care. 
European Journal of Clinical Pharmacology. 2014;70(8):1011-20. 
106. Holstiege J, Schink T, Molokhia M, Mazzaglia G, Innocenti F, Oteri A, et al. 
Systemic antibiotic prescribing to paediatric outpatients in 5 European countries: a 
population-based cohort study. BMC Pediatrics. 2014;14(1):174. 
107. Vodicka TA, Thompson M, Lucas P, Heneghan C, Blair PS, Buckley DI, et al. 
Reducing antibiotic prescribing for children with respiratory tract infections in primary care: 
a systematic review. British Journal of General Practice. 2013;63(612):e445-e54. 
108. Organization WH. WHO report on surveillance of antibiotic consumption: 
2016-2016 early implementation ISBN 978-92-4-151488-0 . License: CC BY-NC-SA 3.0 
IGO. 
109. European Centre for Disease Prevention and Control. Antimicrobial 
consumption in the EU/EEA, annual epidemiological report for 2018. Stockholm: ECDC; 
2019. 
110. Swedres-Svarm 2019. Sales of antibiotics and 
occurrence of resistance in Sweden. Solna/Uppsala ISSN1650-6332. 
111. Control ECfDPa. Antimicrobial consumption in the EU/EEA, annual 
epidemiological report for 2018. 2018. 
112. Jackson C, Hsia Y, Bielicki JA, Ellis S, Stephens P, Wong ICK, et al. 
Estimating global trends in total and childhood antibiotic consumption, 2011-2015. BMJ 
Global Health. 2019;4(1):e001241. 
113. Agency EM. European Medicines Agency, European Surveillance of 
Veterinary Antimicrobial Consumption, 2019 “Sales of veterinary antimicrobial agents in 31 
European countries in 2017”. EMA/294674/2019. 2019. 
114. Van Boeckel TP, Brower C, Gilbert M, Grenfell BT, Levin SA, Robinson TP, 
et al. Global trends in antimicrobial use in food animals. Proceedings of the National 
Academy of Sciences. 2015;112(18):5649-54. 
115. Chantziaras I, Boyen F, Callens B, Dewulf J. Correlation between veterinary 
antimicrobial use and antimicrobial resistance in food-producing animals: a report on seven 
countries. Journal of Antimicrobial Chemotherapy. 2014;69(3):827-34. 
116. Vieira AR, Collignon P, Aarestrup FM, Mcewen SA, Hendriksen RS, Hald T, 
et al. Association Between Antimicrobial Resistance inEscherichia coliIsolates from Food 
Animals and Blood Stream Isolates from Humans in Europe: An Ecological Study. 
Foodborne Pathogens and Disease. 2011;8(12):1295-301. 
117. Valentin L, Sharp H, Hille K, Seibt U, Fischer J, Pfeifer Y, et al. Subgrouping 
of ESBL-producing Escherichia coli from animal and human sources: An approach to 
quantify the distribution of ESBL types between different reservoirs. International Journal of 
Medical Microbiology. 2014;304(7):805-16. 
118. Hammerum AM, Larsen J, Andersen VD, Lester CH, Skovgaard Skytte TS, 
Hansen F, et al. Characterization of extended-spectrum β-lactamase (ESBL)-producing 
Escherichia coli obtained from Danish pigs, pig farmers and their families from farms with 
high or no consumption of third- or fourth-generation cephalosporins. Journal of 
Antimicrobial Chemotherapy. 2014;69(10):2650-7. 
 
76 
119. European Food Safety Authority ECfDPaC. EFSA (European Food Safety 
Authority) and ECDC (European Centre for Disease Prevention and Control), 2020. The 
European Union Summary Report on Antimicrobial Resistance in zoonotic and indicator 
bacteria from humans, animals and food in 2017/2018. EFSA Journal; 2020.  Contract No.: 
2020;18 (3):6007. 
120. Goering Rv DH, Zuckerman M, Wakelin D, Roit IM, Mims C, Chiodini PL. 
Mim's Medical Microbiology, 4th edition2009. 
121. Marturano JE, Lowery TJ. ESKAPE Pathogens in Bloodstream Infections Are 
Associated With Higher Cost and Mortality but Can Be Predicted Using Diagnoses Upon 




123. Herold BC. Community-Acquired Methicillin-Resistant Staphylococcus aureus 
in Children With No Identified Predisposing Risk. JAMA. 1998;279(8):593. 
124. Thorlacius-Ussing L, Sandholdt H, Larsen AR, Petersen A, Benfield T. Age-
Dependent Increase in Incidence of Staphylococcus aureus Bacteremia, Denmark, 2008–
2015. Emerging Infectious Diseases. 2019;25(5). 
125. Gordon O, Cohen MJ, Gross I, Amit S, Averbuch D, Engelhard D, et al. 
Staphylococcus aureus Bacteremia in Children. The Pediatric Infectious Disease Journal. 
2019;38(5):459-63. 
126. Mcmullan BJ, Bowen A, Blyth CC, Van Hal S, Korman TM, Buttery J, et al. 
Epidemiology and Mortality of Staphylococcus aureus Bacteremia in Australian and New 
Zealand Children. JAMA Pediatrics. 2016;170(10):979. 
127. Control. ECfDPa. Surveillance of antimicrobial resistance in Europe 2018. 
Stockholm: ECDC; 2019.; 2019. 
128. Odutola A, Bottomley C, Zaman SA, Lindsay J, Shah M, Hossain I, et al. 
Staphylococcus aureus Bacteremia in Children of Rural Areas of The Gambia, 2008–2015. 
Emerging Infectious Diseases. 2019;25(4):701-9. 
129. Hakim H, Mylotte JM, Faden H. Morbidity and mortality of Staphylococcal 
bacteremia in children. American Journal of Infection Control. 2007;35(2):102-5. 
130. Hultén KG KS, Lamberth LB, Slimp K, Hammerman WA, Carrillo-Marquez 
M, Starke JR, Versalovic J, Mason EO Jr. Hospital-acquired Staphylococcus aureus 
infections at Texas Children's Hospital, 2001-2007. . Infect Control Hosp Epidemiol. 
2010;2(31):7. 
131. Saunderson RB, Gouliouris T, Cartwright EJ, Nickerson EJ, Aliyu SH, 
O'Donnell DR, et al. Impact of infectious diseases consultation on the management of 
Staphylococcus aureus bacteraemia in children. BMJ Open. 2014;4(7):e004659-e. 
132. Lo SW, Gladstone RA, Van Tonder AJ, Lees JA, Du Plessis M, Benisty R, et 
al. Pneumococcal lineages associated with serotype replacement and antibiotic resistance in 
childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-
genome sequencing study. The Lancet Infectious Diseases. 2019;19(7):759-69. 
133. Gounder PP, Brewster M, Bruce MG, Bruden DJT, Rudolph K, Hurlburt DA, 
et al. Impact of the Pneumococcal Conjugate Vaccine and Antibiotic Use on Nasopharyngeal 
Colonization by Antibiotic Nonsusceptible Streptococcus pneumoniae, Alaska, 2000-2010. 
The Pediatric Infectious Disease Journal. 2015;34(11):1223-9. 
134. Luzzaro F, Ortisi G, Larosa M, Drago M, Brigante G, Gesu G. Prevalence and 
epidemiology of microbial pathogens causing bloodstream infections: results of the OASIS 
multicenter study. Diagnostic Microbiology and Infectious Disease. 2011;69(4):363-9. 
135. Pinholt M, Østergaard C, Arpi M, Bruun NE, Schønheyder HC, Gradel KO, et 
al. Incidence, clinical characteristics and 30-day mortality of enterococcal bacteraemia in 
 
 77 
Denmark 2006–2009: a population-based cohort study. Clinical Microbiology and Infection. 
2014;20(2):145-51. 
136. Prematunge C, Macdougall C, Johnstone J, Adomako K, Lam F, Robertson J, 
et al. VRE and VSE Bacteremia Outcomes in the Era of Effective VRE Therapy: A 
Systematic Review and Meta-analysis. Infection Control & Hospital Epidemiology. 
2016;37(1):26-35. 
137. Gouliouris T, Warne B, Cartwright EJP, Bedford L, Weerasuriya CK, Raven 
KE, et al. Duration of exposure to multiple antibiotics is associated with increased risk of 
VRE bacteraemia: a nested case-control study. Journal of Antimicrobial Chemotherapy. 
2018;73(6):1692-9. 
138. Haas EJ ZT, Prasad P, Li M, Coffin SE. Risk Factors and Outcomes for 
Vancomycin-Resistant Enterococcus Bloodstream Infection in Children. . Infect Control 
Hosp Epidemiol. 2010. 
139. CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, 
GA:U.S. Department of Health and Human Services, CDC; 2019. 2019. 
140. Ny S, Löfmark S, Börjesson S, Englund S, Ringman M, Bergström J, et al. 
Community carriage of ESBL-producing Escherichia coli is associated with strains of low 
pathogenicity: a Swedish nationwide study. J Antimicrob Chemother. 2017;72(2):582-8. 
141. Vading M, Kabir MH, Kalin M, Iversen A, Wiklund S, Nauclér P, et al. 
Frequent acquisition of low-virulence strains of ESBL-producing Escherichia coli in 
travellers. J Antimicrob Chemother. 2016;71(12):3548-55. 
142. Logan LK, Meltzer LA, Mcauley JB, Hayden MK, Beck T, Braykov NP, et al. 
Extended-Spectrum  -Lactamase-Producing Enterobacteriaceae Infections in Children: A 
Two-Center Case-Case-Control Study of Risk Factors and Outcomes in Chicago, Illinois. 
Journal of the Pediatric Infectious Diseases Society. 2014;3(4):312-9. 
143. Stapleton PJ, Murphy M, Mccallion N, Brennan M, Cunney R, Drew RJ. 
Outbreaks of extended spectrum beta-lactamase-producing Enterobacteriaceae in neonatal 
intensive care units: a systematic review. Archives of Disease in Childhood - Fetal and 
Neonatal Edition. 2016;101(1):72-8. 
144. Malande OO NJ, Pillay V, Bamford C, Eley B. A ten-year review of ESBL and 
non-ESBL Escherichia coli bloodstream infections among children at a tertiary referral 
hospital in South Africa. PLoS ONE. 2019;9(14(9): e0222675). 
145. Peirovifar A, Ahangarzadeh Rezaee M, Mostafa Gharehbaghi M. Prevalence of 
Multidrug Resistant Extended-SpectrumBeta-Lactamase Producing Gram-Negative Bacteria 
inNeonatal Sepsis. International Journal of Women's Health and Reproduction Sciences. 
2014;2(3):138-45. 
146. Tsai M-H, Chu S-M, Hsu J-F, Lien R, Huang H-R, Chiang M-C, et al. Risk 
Factors and Outcomes for Multidrug-Resistant Gram-Negative Bacteremia in the NICU. 
PEDIATRICS. 2014;133(2):e322-e9. 
147. Roy S, Datta S, Das P, Gaind R, Pal T, Tapader R, et al. Insight into neonatal 
septicaemicEscherichia colifrom India with respect to phylogroups, serotypes, virulence, 
extended-spectrum-β-lactamases and association of ST131 clonal group. Epidemiology and 
Infection. 2015;143(15):3266-76. 
148. Chiotos K, Han JH, Tamma PD. Carbapenem-Resistant Enterobacteriaceae 
Infections in Children. Current Infectious Disease Reports. 2016;18(1). 
149. Kehl SC, Dowzicky MJ. Global Assessment of Antimicrobial Susceptibility 
among Gram-Negative Organisms Collected from Pediatric Patients between 2004 and 2012: 
Results from the Tigecycline Evaluation and Surveillance Trial. Journal of Clinical 
Microbiology. 2015;53(4):1286-93. 
150. Logan LK, Renschler JP, Gandra S, Weinstein RA, Laxminarayan R. 
Carbapenem-ResistantEnterobacteriaceaein Children, United States, 1999–2012. Emerging 
Infectious Diseases. 2015;21(11):2014-21. 
 
78 
151. Schwartz S, Raveh D, Toker O, Segal G, Godovitch N, Schlesinger Y. A week-
by-week analysis of the low-risk criteria for serious bacterial infection in febrile neonates. 
Archives of Disease in Childhood. 2009;94(4):287-92. 
152. Irwin AD, Grant A, Williams R, Kolamunnage-Dona R, Drew RJ, Paulus S, et 
al. Predicting Risk of Serious Bacterial Infections in Febrile Children in the Emergency 
Department. Pediatrics. 2017;140(2):e20162853. 
153. Kuppermann N, Dayan PS, Levine DA, Vitale M, Tzimenatos L, Tunik MG, et 
al. A Clinical Prediction Rule to Identify Febrile Infants 60 Days and Younger at Low Risk 
for Serious Bacterial Infections. JAMA Pediatrics. 2019;173(4):342. 
154. Irwin AD, Wickenden J, Le Doare K, Ladhani S, Sharland M. Supporting 
decisions to increase the safe discharge of children with febrile illness from the emergency 
department: a systematic review and meta-analysis. Archives of Disease in Childhood. 
2016;101(3):259-66. 
155. Woll C, Neuman MI, Aronson PL. Management of the Febrile Young Infant. 
Pediatric Emergency Care. 2017;33(11):748-53. 
156. Lavoie PM, Popescu CR, Molyneux EM, Wynn JL, Chiume M, Keitel K, et al. 
Rethinking management of neonates at risk of sepsis. The Lancet. 2019;394(10195):279-81. 
157. Kuzniewicz MW, Puopolo KM, Fischer A, Walsh EM, Li S, Newman TB, et 
al. A Quantitative, Risk-Based Approach to the Management of Neonatal Early-Onset Sepsis. 
JAMA Pediatrics. 2017;171(4):365. 
158. Watt JP, Wolfson LJ, O'Brien KL, Henkle E, Deloria-Knoll M, Mccall N, et al. 
Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: 
global estimates. The Lancet. 2009;374(9693):903-11. 
159. Laxminarayan R, Matsoso P, Pant S, Brower C, Røttingen J-A, Klugman K, et 
al. Access to effective antimicrobials: a worldwide challenge. The Lancet. 
2016;387(10014):168-75. 
160. Galanis I, Lindstrand A, Darenberg J, Browall S, Nannapaneni P, Sjöström K, 
et al. Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in 
Stockholm, Sweden. European Respiratory Journal. 2016;47(4):1208-18. 
161. Schrag SJ, Verani JR. Intrapartum antibiotic prophylaxis for the prevention of 
perinatal group B streptococcal disease: Experience in the United States and implications for 
a potential group B streptococcal vaccine. Vaccine. 2013;31:D20-D6. 
162. Stoll BJ HN, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, Lemons 
JA, Donovan EF, Stark AR, Tyson JE, Oh W, Bauer CR, Korones SB, Shankaran S, Laptook 
AR, Stevenson DK, Papile LA, Poole WK. Late-Onset Sepsis in Very Low Birth Weight 
Neonates: The Experience of the NICHD Neonatal Research Network. Pediatrics. 2002 
Aug;110:6. 
163. Manzoni P, Stolfi I, Pugni L, Decembrino L, Magnani C, Vetrano G, et al. A 
Multicenter, Randomized Trial of Prophylactic Fluconazole in Preterm Neonates. New 
England Journal of Medicine. 2007;356(24):2483-95. 
164. Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Donowitz LG. 
Fluconazole Prophylaxis against Fungal Colonization and Infection in Preterm Infants. New 
England Journal of Medicine. 2001;345(23):1660-6. 
165. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-
Zeichner L, et al. Executive Summary: Clinical Practice Guideline for the Management of 
Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious 
Diseases. 2016;62(4):409-17. 
166. Austin N, Cleminson J, Darlow BA, Mcguire W. Prophylactic oral/topical non-
absorbed antifungal agents to prevent invasive fungal infection in very low birth weight 
infants. Cochrane Database of Systematic Reviews. 2015. 
 
 79 
167. Science M, Robinson PD, Macdonald T, Rassekh SR, Dupuis LL, Sung L. 
Guideline for primary antifungal prophylaxis for pediatric patients with cancer or 
hematopoietic stem cell transplant recipients. Pediatric Blood & Cancer. 2014;61(3):393-400. 
168. Lehrnbecher T, Fisher BT, Phillips B, Alexander S, Ammann RA, Beauchemin 
M, et al. Guideline for Antibacterial Prophylaxis Administration in Pediatric Cancer and 
Hematopoietic Stem Cell Transplantation. Clinical Infectious Diseases. 2020;71(1):226-36. 
169. Henderson KL, Müller-Pebody B, Wade A, Sharland M, Minaji M, Johnson 
AP, et al. Timing of positive blood samples does not differentiate pathogens causing 
healthcare-associated from community-acquired bloodstream infections in children in 
England: a linked retrospective cohort study. Epidemiology and Infection. 
2015;143(11):2440-5. 
170. CDC. BSI-surveillance-definitions_v6.0-cdcb-ics-20190116.pdf. 2019. 
171. Nordberg V. Every bugs counts: neonatal colonization and infection of Gram-
negative bacilli - aspects on antibiotic resistance in Sweden and Ecuador. Thesis at 
Karolinska Institutet October 2020 . 
172. Ladhani SN, Henderson KL, Muller-Pebody B, Ramsay ME, Riordan A. Risk 
of invasive bacterial infections by week of age in infants: prospective national surveillance, 
England, 2010-2017. Arch Dis Child. 2019;104(9):874-8. 
173. Gomez B, Diaz H, Carro A, Benito J, Mintegi S. Performance of blood 
biomarkers to rule out invasive bacterial infection in febrile infants under 21 days old. Arch 
Dis Child. 2019;104(6):547-51. 
174. Pilishvili T, Lexau C, Farley M, Monica, Hadler J, Harrison H, Lee, Bennett M, 
Nancy, et al. Sustained Reductions in Invasive Pneumococcal Disease in the Era of 
Conjugate Vaccine. The Journal of Infectious Diseases. 2010;201(1):32-41. 
175. Klugman KP, Black S. Impact of existing vaccines in reducing antibiotic 
resistance: Primary and secondary effects. Proceedings of the National Academy of Sciences. 
2018;115(51):12896-901. 
176. Jit M. The risk of sequelae due to pneumococcal meningitis in high-income 
countries: A systematic review and meta-analysis. Journal of Infection. 2010;61(2):114-24. 
177. Naucler P, Galanis I, Morfeldt E, Darenberg J, Örtqvist Å, Henriques-Normark 
B. Comparison of the Impact of Pneumococcal Conjugate Vaccine 10 or Pneumococcal 
Conjugate Vaccine 13 on Invasive Pneumococcal Disease in Equivalent Populations. Clinical 
Infectious Diseases. 2017;65(11):1780-90.e1. 
178. Ladhani SN, Collins S, Djennad A, Sheppard CL, Borrow R, Fry NK, et al. 
Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England 
and Wales, 2000–17: a prospective national observational cohort study. The Lancet 
Infectious Diseases. 2018;18(4):441-51. 
179. Edmond KM, Kortsalioudaki C, Scott S, Schrag SJ, Zaidi AK, Cousens S, et al. 
Group B streptococcal disease in infants aged younger than 3 months: systematic review and 
meta-analysis. The Lancet. 2012;379(9815):547-56. 
180. O'Sullivan CP, Lamagni T, Patel D, Efstratiou A, Cunney R, Meehan M, et al. 
Group B streptococcal disease in UK and Irish infants younger than 90 days, 2014–15: a 
prospective surveillance study. The Lancet Infectious Diseases. 2019;19(1):83-90. 
181. Ecker KL, Donohue PK, Kim KS, Shepard JA, Aucott SW. The impact of 
group B streptococcus prophylaxis on late-onset neonatal infections. Journal of Perinatology. 
2013;33(3):206-11. 
182. Tapiainen T, Koivusaari P, Brinkac L, Lorenzi HA, Salo J, Renko M, et al. 
Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of 
antimicrobial resistance in infants. Scientific Reports. 2019;9(1). 
183. Glasgow TS, Speakman M, Firth S, James B, Byington CL, Young PC. Clinical 
and economic outcomes for term infants associated with increasing administration of 
antibiotics to their mothers. Paediatric and Perinatal Epidemiology. 2007;21(4):338-46. 
 
80 
184. Bizzarro MJ DL, Baltimore RS, Gallagher PG. Changing patterns in neonatal 
Escherichia coli sepsis and ampicillin resistance in the era of intrapartum antibiotic 
prophylaxis. . Pediatrics. 2008;121(4):5. 
185. Davies H, MBChB, MSc, Carreras-Abad, Clara, et al. Group B Streptococcus: 
Trials and Tribulations. Pediatr Infect Dis J. 2019;38:4. 
186. Rios JFDS, Camargos PAM, Corrêa LP, Romanelli RMDC. Fluconazole 
prophylaxis in preterm infants: a systematic review. The Brazilian Journal of Infectious 
Diseases. 2017;21(3):333-8. 
187. Vergnano S, Menson E, Smith Z, Kennea N, Embleton N, Clarke P, et al. 
Characteristics of Invasive Staphylococcus aureus in United Kingdom Neonatal Units. 
Pediatr Infect Dis J. 2011;30(10):850-4. 
188. Denniston S, Riordan FA. Staphylococcus aureus bacteraemia in children and 
neonates: a 10 year retrospective review. J Infect. 2006;53(6):387-93. 
189. Droz N, Hsia Y, Ellis S, Dramowski A, Sharland M, Basmaci R. Bacterial 
pathogens and resistance causing community acquired paediatric bloodstream infections in 
low- and middle-income countries: a systematic review and meta-analysis. Antimicrobial 
Resistance & Infection Control. 2019;8(1). 
190. Tängdén T CO, Melhus A, Löwdin E. Foreign travel is a major risk factor for 
colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-
lactamases: a prospective study with Swedish volunteers. . Antimicrob Agents Chemother. 
2010;9(54):4. 
191. Zaoutis TE, Goyal M, Chu JH, Coffin SE, Bell LM, Nachamkin I, et al. Risk 
factors for and outcomes of bloodstream infection caused by extended-spectrum beta-
lactamase-producing Escherichia coli and Klebsiella species in children. Pediatrics. 
2005;115(4):942-9. 
192. Lukac PJ, Bonomo RA, Logan LK. Extended-Spectrum  -Lactamase-Producing 
Enterobacteriaceae in Children: Old Foe, Emerging Threat. Clinical Infectious Diseases. 
2015. 
193. Folgori L, Bielicki J. Future Challenges in Pediatric and Neonatal Sepsis: 
Emerging Pathogens and Antimicrobial Resistance. J Pediatr Intensive Care. 2019;8(1):17-
24. 
194. Nordberg V, Quizhpe Peralta A, Galindo T, Turlej-Rogacka A, Iversen A, 
Giske CG, et al. High Proportion of Intestinal Colonization with Successful Epidemic Clones 
of ESBL-Producing Enterobacteriaceae in a Neonatal Intensive Care Unit in Ecuador. PLoS 
ONE. 2013;8(10):e76597. 
195. Cailes B, Vergnano S, Kortsalioudaki C, Heath P, Sharland M. The current and 
future roles of neonatal infection surveillance programmes in combating antimicrobial 
resistance. Early Human Development. 2015;91(11):613-8. 
196. Aminov RI. The role of antibiotics and antibiotic resistance in nature. Environ 
Microbiol. 2009;11(12):2970-88. 
197. Martinez JL. Environmental pollution by antibiotics and by antibiotic resistance 
determinants. Environ Pollut. 2009;157(11):2893-902. 
198. Holmes AH, Moore LS, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al. 
Understanding the mechanisms and drivers of antimicrobial resistance. Lancet. 
2016;387(10014):176-87. 
199. Gharbi M, Doerholt K, Vergnano S, Bielicki JA, Paulus S, Menson E, et al. 
Using a simple point-prevalence survey to define appropriate antibiotic prescribing in 
hospitalised children across the UK. BMJ Open. 2016;6(11):e012675. 
200. De Luca M, Donà D, Montagnani C, Lo Vecchio A, Romanengo M, Tagliabue 
C, et al. Antibiotic Prescriptions and Prophylaxis in Italian Children. Is It Time to Change? 
Data from the ARPEC Project. PLOS ONE. 2016;11(5):e0154662. 
 
 81 
201. Patel SV, Vergnano S. The impact of paediatric antimicrobial stewardship 
programmes on patient outcomes. Curr Opin Infect Dis. 2018;31(3):216-23. 
202. Donà D, Barbieri E, Daverio M, Lundin R, Giaquinto C, Zaoutis T, et al. 
Implementation and impact of pediatric antimicrobial stewardship programs: a systematic 
scoping review. Antimicrobial Resistance & Infection Control. 2020;9(1). 
203. Björkman L, Ohlin A. Scrubbing the hub of intravenous catheters with an 
alcohol wipe for 15 sec reduced neonatal sepsis. Acta Paediatrica. 2015;104(3):232-6. 
204. Caspari L, Epstein E, Blackman A, Jin L, Kaufman DA. Human factors related 
to time-dependent infection control measures: “Scrub the hub” for venous catheters and 
feeding tubes. American Journal of Infection Control. 2017. 
205. Pronovost P, Needham D, Berenholtz S, Sinopoli D, Chu H, Cosgrove S, et al. 
An Intervention to Decrease Catheter-Related Bloodstream Infections in the ICU. New 
England Journal of Medicine. 2006;355(26):2725-32. 
 
